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1 Introduction 
 “Boy, that escalated quickly. I mean, that really got out of hand fast.” 
Ron Burgundy 
Antimicrobial resistance is ever-evolving around us. The emergence of 
Enterobacterales producing extended spectrum beta-lactamases (ESBL) has been 
correlated  to the introduction of third generation cephalosporins in healthcare 
settings (1). Infections due to multidrug-resistant Enterobacterales constitute a 
major health care concern and are associated with increased mortality compared to 
infections with third generation-susceptible Enterobacterales (2-5). Treatment 
options for such infections are few. Intestinal colonization of Escherichia coli 
and/or Klebsiella pneumoniae producing ESBL is a requirement for developing 
such infections (6). It is vital to learn more  about the  mechanisms, spread and 
impact of ESBL-producing Enterobacterales (EPE). 
The theme of this thesis is intestinal colonization of ESBL-producing E. coli and K. 
pneumoniae, the most common bacteria carrying this particular resistance. The 
primary aim of this thesis is to investigate transmission, risk factors for prolonged 
colonization, eradication and international travel as a risk factor for intestinal 
colonization of EPE.  
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2 The normal gut flora  
The microbiota is defined as a population of microbes that inhabits a given 
ecosystem. The combined genetic material of the microbes in the defined microbiota 
is called the microbiome. Each individual carries unique sets of bacteria and genes. 
The intestinal microbiota of people living in different countries is distinctly 
different, due to many factors of which dietary differences are one (7, 8). Each 
bacterial strain, and the genomes of viruses, fungi and archaea in the intestine, 
together carry thousands of genes. This makes the intestinal microbiome far more 
versatile than our own human genome.  
Structure 
The human intestines contain an estimated 500-1000 species of bacteria, in total 
about 1010 – 1011 bacterial cells per gram of faeces (9). The total amount of bacteria 
in the intestines was previously estimated to 1014. However, a newer assessment of 
the total amount of bacteria in the body of an average adult of 70 kg weight is closer 
to trillions of bacteria (1012). The total weight of these bacteria is 0.2 kg, about 0.3 
% of the total body weight of a 70 kg adult (10). The total amount of bacteria in the 
body roughly equals the total number of cells in the body, as opposed to older 
estimates of 10:1 in favour of bacteria. The rich supply of nutrients in the gut 
provides an excellent microclimate for the bacteria. 
The microbiota is often compared to a human organ and it also includes, e.g., 
microbes covering skin, teeth and mucous membranes and inhabits the border 
between the body and the surrounding milieu (11). Most interactions between the 
body and the surrounding environment involves bacteria to some extent.  
Function 
The function of the microbiota is versatile, and the full extent of its purposes is 
presently unknown. One important function of the microbiota is digestion of dietary 
fibre that are indigestible by human enzymes (12). This has the dual effect of 
providing the body with energy that would otherwise have been lost; as well as with 
a vast array of e.g., short chain fatty acids (SCFAs), potent regulatory physiological 
molecules (13). Furthermore, the microbiota is involved in the development of the 
immune system, host intestinal endocrine function, provides protection against the 
adhesion of pathogenic bacteria, synthesis of vitamins and neurotransmitters and 
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acts as eliminator of toxins (14, 15). The function of inter-species interactions is, 
however, currently under-explored. 
The gastrointestinal tract covers about 30 m2 of mucous membrane and thus a single 
stool sample, or a faecal culture, is a poor representative of the entire microbiota. A 
faecal culture is a poor model for grasping the complexity of the “true” microbiota. 
Most bacteria of the microbiota are unculturable with standard techniques, and 
recent technological advances has enabled advanced analyses of the microbiota.  
Development 
The normal gut microbiota is established during infanthood and is affected by a 
number of different factors, including mode of delivery, feeding/diet, antibiotic use 
and consumption of probiotics (7, 12, 15). The supply of breastmilk is the most 
significant factor of microbiota structure during the first year. After the cessation of 
breast feeding, the microbiota continues to develop rapidly. It is dominated by 
phylum Bacteroidetes and Firmicutes, of which the main genera are Bacteroides, 
and Bacillus and Clostridium, respectively (16). The most common genus found in 
the gut is Bacteroides. It also contains, in smaller proportions, Actinobacteria, 
Proteobacteria, Verrucomicrobia, and other microorganisms as Archaea, yeasts and 
phages (14).  
The ability of bacteria to effectively colonize the intestines is in large part 
determined by the presence of oxygen. The majority of the bacteria in the colon are 
anaerobe bacteria. 
The role in disease 
Ordinarily, a stable equilibrium state exists between the individual and the 
microbiota, a symbiosis. In contrast, the term dysbiosis is often used to describe a 
state where the host-microbial balance is disturbed in a way that is detrimental to 
the host. This is often associated with a loss of diversity and a low-grade 
inflammation of the intestinal mucosa. Dysbiosis is context and disease specific. 
Dysbiosis of the microbiota has been associated with the disease progression of 
numerous diseases, including diabetes mellitus and IBD (17).  
A decrease in diversity of the microbiota is associated with several diseases, 
including IBD, obesity, diabetes or recurrent infection with Clostridioides difficile. 
Additionally, some strains of bacteria seem to be specific of IBD (18). Microbiota 
composition have also been demonstrated to affect the response to cancer treatment 
(19). It is important to note, that these associations have not been established as 
causative. It is presently unknown if the altered microbiota is a cause or result of the 
disease in question (15). In mechanistic animal models of human disease, the 
microbiome is involved in the pathogenesis of autoimmune disease, obesity and 
neurological diseases. This causality has not been established in humans. 
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The resilience phenomenon is the ability of the gut flora to return to an equilibrium 
state following a disturbance. A disturbance of the microbiota can be chemical (e.g. 
antibiotics), physical (e.g. diarrhoea), microbial (e.g. probiotics). The resilience is 
associated with the diversity of the microbiota; the more diverse, the more easily 
will equilibrium be restored (17). In parallel, a more varied gut microbiota is less 
susceptible to disturbance (17). This could be related to human health; a person with 
a healthy microbiota with a high level of resilience may have better protection 
against dysbiosis and infection (11).  
EPE and the microbiota 
As the topic of this thesis is EPE, this leads to two fundamental questions; what is 
the role of ESBL-producing Enterobacterales in the microbiome? What is the role 
of the microbiome in protecting against colonization and persistence of ESBL-
producing bacteria in relation to other risk factors?  
Presently, to my knowledge, studies on this topic are limited. 
Studies on travellers returning from areas endemic of EPE show high prevalence of 
EPE colonization, with or without traveller’s diarrhoea or antibiotic consumption 
during the trip (20-25). Strains of E. coli not producing CTX-M types are 
simultaneously acquired during travel. In colonizing the intestines, EPE are often 
polyclonal, and they seem to at least temporarily replace strains of commensal E. 
coli (26). How this is done is unknown, one theory is that the EPE could induce a 
small inflammatory response, which releases by-products that can be used in 
anaerobic metabolism. The invading EPE strain is able to use these substrates more 
efficiently than the commensal E. coli. This leads to a competitive growth advantage 
and the EPE strain can displace the commensal E. coli (27). Prolonged colonization 
of EPE enables further dissemination to new hosts. 
2.1 Colonization resistance 
Colonization resistance is the ability to prevent pathogenic bacteria to adhere and 
grow in the intestines. The association between the microbiota and host defence was 
made decades ago when mice with dysbiosis (post antibiotic exposure) were shown 
to have an increased risk of enteric infection (28). The precise mechanism in which 
pathogenic bacteria are prevented from colonizing the intestines of a healthy gut is 
not fully comprehended, but it involves competing for nutrients, production of 
antimicrobial products, gut barrier integrity and distribution of bacteriophages (29). 
Examples of antimicrobial products are bile acids, bacteriocins and short chain fatty 
acids. 
A prospective Swedish study found that travellers with a less diverse microbiota 
were more susceptible to Campylobacter infection (30). Antibiotics do not differ 
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between pathogenic or commensal bacteria and may promptly induce dysbiosis 
(31). Consequently, this can increase the risk of pathogenic or opportunistic bacteria 
colonizing and infecting the intestines of which C. difficile is a notable and clinically 
relevant example (32). As a consequence of antimicrobial treatment, overgrowth of 
toxin-producing C. difficile can result in enteritis and disease. Interestingly, 
colonization with Clostridiales is also associated with increased colonization 
resistance (12). 
Commensal strains of E. coli and EHEC compete for signals and nutrients produced 
by bacteria in the gut. In mice, multiple strains of commensal E. coli with similar 
nutritional requirements as EHEC prevent the latter from colonizing the intestines 
(32). Another study linked colonization resistance to an acidic environment with 
production of high concentrations of short fatty acids- this inhibited the expansion 
and supported clearance of EPE among others (33). 
In a study on mice, the antibiotics clindamycin, dicloxacillin and cefotaxime all 
promoted the overgrowth of and CTX-M-15-producing E. coli ST131. Of these, 
only clindamycin was associated with both the suppression of Bacteroides and 
prolonged colonization of the CTX-M-15-producing E. coli ST131 (34). 
In addition to antibiotics, many other classes of drugs can impact the microbiota, 
such as proton pump inhibitors, antidiabetics and antipsychotics (29). 
Furthermore, a continuous stress to the microbiota, as in a permanent dietary switch 
from high protein diet to a carbohydrate rich diet (or vice versa), could permanently 
alter the microbiota in what is sometimes called a ‘regime shift’ (17).   
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3 Escherichia coli 
Escherichia coli was named after the German paediatrician Theodor Escherich 
(1857-1911), who first described the bacterium in 1886 (35). E. coli is a Gram-
negative, rod shaped, non-sporulating facultative anaerobe, found in humans and 
warm-blooded animals. The pathogenic range of E. coli is vast; it is a common 
commensal of the intestines but also a potentially severe pathogen leading to severe 
sepsis and death. Thus, the within-species diversity of E. coli is immense. Profound 
knowledge of the resistance and pathogenicity of E. coli has been gained since it is 
an exemplary bacterium to work with in the laboratory; it grows easily, fast and its 
genome has been thoroughly investigated. 
In the intestines, the concentration of E. coli is 107 -109 cfu per gram of faeces (36). 
The intestinal concentration of E. coli is highest early in life. In two thirds of 
vaginally delivered babies, the source of the E. coli is maternal, the rest are 
environmental strains (37). This is true for the entire microbiota of vaginally 
delivered babies, as it is similar to the vaginal and gut microbiota of the mother (14). 
The microbiota of babies born with caesarean section is less diverse compared to 
vaginally delivered babies (15). 
At two years of age, the amount of E. coli stabilizes around 108 cfu per gram of 
faeces and then decreases gradually with age. Thus, depending on age, between 
0.01-10% of all bacteria in the gut are E. coli, primarily located in large intestine. 
Infections caused by E. coli can be both intestinal and extraintestinal, depending on 
bacterial characteristics. This is in turn based on the extent of virulence factors 
expressed to overcome the immune system of the host. Strains causing 
extraintestinal disease are unable to cause intestinal disease, and vice versa (38). 
During the past decades, detailed knowledge of E coli genes, of both chromosomal 
and plasmid origin, has been acquired through new sequencing methods on strains 
causing disease in humans. This has increased knowledge regarding the 
pathogenicity of E. coli and led to better categorization of the different types that 
exist. 
Clinically important strains of E. coli to humans can be divided into commensal 
strains, intestinal pathogenic or extraintestinal pathogenic E. coli (ExPEC) (38). 
Infections caused by ExPEC strains can be non-severe, e.g. lower urinary tract 
infections (i.e. symptomatic, not causing severe disease), or severe life-threatening 
infections, such as septic shock. The true population-based incidence rate of 
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worldwide E. coli infections is not known, and different models exist predicting this, 
but an estimated two million people perish every year from E. coli infections 
globally (38-40). 
Commensal E. coli  lack virulence factors that are generally needed to cause disease 
in hosts without compromised immune systems. By adherence to the intestines, 
production of bacteriocins and other mechanisms, they protect the host against 
colonisation of other bacteria with greater pathogenicity (36). In severely 
immunocompromised hosts, however, commensal E. coli can act as opportunists 
and cause extraintestinal infection (41).  
Intestinal pathogenic E. coli are commonly divided into five different pathotypes; 
EAEC, EHEC, EIEC, EPEC and ETEC. Although there is overlap between them, 
these pathotypes each have a combination of specific virulence factors giving them 
each individual pathogenic potential (35). When the host is infected with a sufficient 
number of bacteria, each of these pathotypes can cause gastroenteritis and/or colitis. 
Thus, clinically, the symptomatology of the different intestinal pathogenic E. coli is 
shared and cannot be used as a basis to differ between them. For this, molecular 
methods such as PCR must be used. The treatment of patients with infections by 
intestinal pathogenic E. coli is primarily symptomatic. 
Inflammation of the gut causes expansion of E. coli which in turn can lead to 
transmission to new hosts through faecal-oral route. Consequently, strains that cause 
enteritis and disease can spread more successfully and have thus been favoured in 
the natural selection, outcompeting less virulent strains. All bacteria in the intestines 
compete for the same nutrients and a limited space of mucous membrane to adhere 
to.  
ExPEC are defined as all non-commensal E. coli isolates able to cause extra-
intestinal disease, in numerous anatomical sites (41). Common foci include the 
blood, urinary tract, abdomen and the meninges. ExPEC strains share similar 
genetic traits, such as a range of virulence factors. Interestingly, ExPEC do not cause 
gastroenteritis, but colonizes the intestines of the healthy host prior to extra-
intestinal infection (42). For extra-intestinal infection to occur, the bacteria must 
depart the intestines and enter an extra-intestinal site, such as the urinary tract. This 
ability is what differentiates ExPEC from commensal strains and is reflected in the 
possession of specific virulence factors. As presented schematically in Figure 1, 
general E. coli virulence factors include toxins (e.g. hemolysin), adhesins (e.g. P- 
and S-fimbriae), iron-acquisition systems (e.g. aerobactin) and host defence-
avoidance mechanisms.  
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Figure 1. Schematic presentation of E. coli virulence factors. 
Fimbriae are used to adhere to host epithelial cells of the intestines, kidneys or lower urinary tract. Exotoxins and 
membrane bound toxins can be secreted to damage host cells or disrupt normal cellular metabolism. Iron-acquisition 
systems (siderophores) are used to obtain essential iron molecules. The LPS stabilize the membrane structure and 
can induce a severe reaction from the immune system of the host. The capsule can mimic cells of the host, thereby 
evading cells of the immune system.The flagellum is mainly used for movement but also serves as a sensory 
organelle. 
For instance, E. coli in the blood originating from an pyelonephritis is associated 
with the expression of P-fimbriae (42). Expression of multiple virulence factors is 
more common in E. coli causing pyelonephritis or urosepsis compared to strains 
causing lower UTI or ABU (42). 
Genes encoding for virulence factors are often concentrated together in 
pathogenicity-associated islands (PAIs), which are blocks of chromosomal DNA, or 
alternatively on plasmids (43, 44).  
Using molecular methods, ExPEC are defined as E. coli carrying two or more of the 
following VFs in the genome; papA and/or papC, sfa/foc, afa/draBC, kpsM II and 
iutA (45). 
E. coli can be further divided into phylogroups of which there are 8 documented; A, 
B1, B2, D, E, F, G and Clade 1. Although colonization with E. coli of B2 is common, 
this phylogroup is the one most often associated with virulence and extra-intestinal 
infections (44). ExPEC strains most often belong to phylogroups B2 or D in non-
immunocompromised individuals, while commensal E. coli and intestinal 
pathogenic E. coli most often belong to A/B1 or A/B1/D, respectively (44). 
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3.1 Klebsiella pneumoniae 
Klebsiella pneumoniae was named after the German pathologist Edwin Klebs 
(1834-1913). It was first described by Carl Friedlander in 1882, isolated from the 
lungs of patients who had died from pneumonia (46). Klebsiella pneumoniae is a 
Gram-negative, rod shaped, encapsulated, facultative anaerobic, non-sporulating 
bacteria. It colonizes the intestines of humans and animals and is also found in the 
environment, e.g. in the soil and in plants. In humans, it is the most clinically 
important bacteria of the genus, but K. oxytoca can also, rarely, cause disease. 
Klebsiella pneumoniae is classified as an ESKAPE pathogen, along with 
Enterococcus faecium, Staphylococcus aureus, Acinetobacter baumannii, 
Pseudomonas aeruginosa and Enterobacter species (47). The ESKAPE pathogens 
are associated with antimicrobial resistance and are recognized as priority pathogens 
for which new antibiotics are urgently needed. Klebsiella pneumoniae, as well as 
the other ESKAPE pathogens, are associated with nosocomial infections, often seen 
in immunocompromised patients with multiple comorbidities. It has been estimated 
that K. pneumoniae cause 8 % of all nosocomial bacterial infections in Europe and 
in the United States (48). Thus, it can be an opportunistic pathogen with nosocomial 
spread, responsible for one third of all Gram-negative hospital infections in total 
(49). However, during recent years, K. pneumoniae with increased virulence and 
widespread antimicrobial resistance have emerged, with the ability to cause diseases 
in immunocompetent hosts. Compared to E. coli, K. pneumoniae is generally less 
susceptible to several classes of antibiotics when compared to E. coli, especially to 
cephalosporins and carbapenems. Compared to E. coli, invasive infections with K. 
pneumoniae are more often nosocomial, frequently affect patients with multiple 
comorbidities and are associated with higher mortality (50). 
Due to its ability to colonize the environment and spread rapidly, in-hospital 
transmission and outbreaks of nosocomial infections of K. pneumoniae occur 
worldwide, especially in neonatal units (48). Nosocomial infections are primarily 
lung and urinary tract infections.  In hospitals, the colonization rates of K. 
pneumoniae in patients increases proportionally with the length of stay and is 
facilitated by antibiotic usage, concordant with other nosocomial pathogens 
common in hospital flora such as P. Aeruginosa (51). Reducing antibiotic 
consumption in general, and fluoroquinolones and cephalosporins in particular, can 
reduce the risk of hospital outbreaks, along with improved hygiene measures and 
infection control (52). 
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3.2 Dominant clones 
The word clone is derived from the ancient Greek word klon, meaning twig. It is 
defined as a cell (bacteria) that is genetically identical to the organism from which 
it is derived. In the past decades, virulent clones of E. coli have emerged with global 
dissemination. These clones represent lineages of E. coli that can carry virulence 
and resistance genes which enables further transmission, of which the clone B2 
O25:H4 ST131 carrying CTX-M-15 is the most prominent example (43). The 
ST131 lineage of ESBL-producing E. coli was first described in 2008 as a common 
cause of hospital infections in many countries. Recently, molecular studies have 
estimated the emergence of this clone in the early 1990s in North America, likely 
stimulated by the broad usage of extended spectrum cephalosporins and 
fluoroquinolones (53). Other notable clones are ST410 and ST648 (27).  
Unlike E. coli, there seem to be geographical limits in the dissemination of different 
K. pneumoniae clones, i.e. not pandemically spread. Also, unlike E. coli, dominant 
clones of K. pneumoniae (such as ST11) to a greater extent carry genes conferring 
resistance to both cephalosporins and carbapenems, sometimes including colistin 
(27). A common trait of both E. coli and K. pneumoniae is that the successful spread 
of dominant clones is facilitated by plasmids. 
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4 Colonization versus infection 
The transmission of EPE is complex and must be viewed from a one-health 
perspective. The gastrointestinal tract of humans and animals are reservoirs for EPE, 
and EPE can increasingly be found in the environment (54). EPE can spread 
between humans both within the community and in hospitals and could be driven 
by international travel to EPE endemic areas. 
 
Figure 2. Schematic presentation of important reservoirs of EPE. 
Figure reprinted with permission from author Paul-Louis Woerther (55). 
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It is widely accepted that intestinal colonization with EPE is the sine qua non of 
developing subsequent infections from EPE (6). Once colonized by EPE, the risk of 
developing serious EPE infections is relatively low, and mainly occurs within a year 
of detecting EPE (56, 57). A Swedish study showed that the pathogenicity of faecal 
strains is lower compared to invasive EPE strains (58). However, many studies 
acknowledge prior EPE colonization as an important risk factor of developing 
invasive EPE infections (59-61). 
Distinguishing EPE infection from colonization is imperative and can be a challenge 
when seeing patients in the clinic. If EPE is found in cultures from sterile sites, such 
as the blood, joints or cerebrospinal fluid, a clinician can be certain that the patient 
has a manifest, clinically relevant, infection which must be promptly treated with 
antibiotics. However, when EPE are found in other cultures, e.g. from urine, skin or 
sputum, the situation is much more precarious. It could represent an infection but 
also mere colonization. Patients are frequently colonized by EPE in other 
localizations than the gastrointestinal tract. In these cases, the EPE strains are likely 
commensals and should rarely be treated with antibiotics. It is of uttermost 
significance to differentiate between these two situations, as antimicrobial treatment 
of colonization does not permanently eradicate colonization but increases the risk 
of  selection and persistence of resistant, virulent EPE clones (62). 
Sometimes quantification of bacteria is used to try to distinguish between 
colonisation and infection, examples are urine and lower airways of intubated 
patients. However, there are currently no biomarkers that can differentiate between 
infection and colonisation. Thus, unless for infection control purposes, cultures 
should only be taken if there is a clinical suspicion of infection.  
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5 The beta-lactams  
Beta-lactam antibiotics are arguably the most effective and widely used class of 
antimicrobials. Since sir Alexander Fleming discovered the antibacterial properties 
of penicillin in 1928, beta-lactam antibiotics have continued to dominate the market 
of antibiotic production and consumption (63). Beta-lactam antibiotics are 
characterized by the beta-lactam ring, the principal structure of penicillins, 
cephalosporins, carbapenems and monobactams. Beta-lactams were originally 
derived from naturally occurring substances; penicillin was derived from the fungi 
Penicillium notatum. Today, the producer organisms of beta-lactams are Penicillium 
chrysogenum and Acremonium chrysogenum (63). 
 
Figure 3. The molecular structure of a) the beta-lactam ring, b) penicillin and c) cephalosporin. Note the fundamental 
beta-lactam ring in red. 
 ‘Beta-lactam antibiotics inhibit the synthesis and the maintenance of the bacterial 
cell wall, in particular the formation and remodelling of the polymer peptidoglycan. 
Under normal circumstances, the bacterial peptidoglycan is formed by the cross-
linking of beta-linked N-acetylglucosamine (GlcNAc) and N-acetylmuramic acid 
(MurNAc) polysaccharide chains, which produces a rigid three-dimensional 
structure (64). This process is called the transpeptidation. The enzymes DD-
transpeptidase, commonly referred to as penicillin binding proteins (PBP), aid this 
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process by catalysis. There are several different variants of PBPs, each targeted by 
different beta-lactam antibiotics. 
The peptidoglycan and PBP during normal conditions. Note the cross linking of 
sugars and amino acids. This is the basis for maintaining bacterial cell structure 
integrity. 
Figure 4. Schematic presentation of mechanism of action of beta-lactam antibiotics. 
The PBPs are inhibited by beta-lactam antibiotics, disrupting cross linkage between 
peptidoglycans. This leads to bacterial lysis. 
The beta-lactam ring inhibits the PBP, which prevents transpeptidation. As a result, 
the peptidoglycan is not properly formed, cell wall integrity cannot be maintained, 
leading to lysis of the bacterial cell. Thus, beta-lactams are bactericidal and highly 
effectively in killing bacteria. Side effects and adverse events are few, with no effect 
on eukaryotic cells. Gastrointestinal symptoms during treatment are common, as the 
effect is not limited to pathogenic bacteria, but to commensal bacteria of the 
microbiota as well. Since the introduction of beta-lactam antibiotics, however, they 
have been pursued by clinically significant resistance. 
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5.1 A brief history of beta-lactamases  
Brace yourself, I'll take you on a trip down memory lane. 
Kendrick Lamar 
Since the 1960s, a broad diversity of different beta-lactamases has been discovered. 
Not surprisingly, they emerged shortly after the introduction of corresponding beta-
lactam antibiotics into healthcare . Figure 3 shows the timeline of the most 
prominent beta-lactamases. 
 
Figure 3. Timeline of the first identification of various beta-lactamases. 
5.1.1 TEM 
The first plasmid-mediated beta-lactamase of Gram-negative bacteria was 
discovered during the 1960s in Greece. It was isolated from a strain of E. coli found 
in a blood culture of a patient, Temoneira, thus naming the enzyme TEM (65). 
Gradually, as antibiotic consumption increased, TEM became more prevalent in 
health care settings worldwide. TEM can be found in bacteria of the 
Enterobacterales, in Pseudomonas aeruginosa, Haemophilus influenzae and in 
Neisseria gonorrhoeae. Not long after that, TEM-2 was found, a closely related 
beta-lactamase only differing one amino acid from TEM-1 (66). TEM-1 and TEM-
2 are active against narrow spectrum cephalosporins, such as cephalothin, but not 
third generation cephalosporins. Further mutations have led to TEM-type ESBLs, 
conferring resistance to third generation cephalosporins. 
5.1.2 SHV 
Sulfhydryl variable beta-lactamase (SHV-1) emerged in the 1970s as a similar but 
less common beta-lactamase (67). TEM-1, TEM-2 and SHV-1 have no activity 
against cefotaxime, ceftazidime or aztreonam. During the 1980s antibiotics with 
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broader spectra were introduced in health care and the use of third generation 
cephalosporins became widespread in hospitals all over the world. As a direct 
consequence, new beta-lactamases appeared. The first of these with activity against 
third generation cephalosporins such as cefotaxime was named SHV-2 (68). It was 
found in Klebsiella ozeanae in Germany. 
5.1.3 CTX-M-type beta-lactamases 
During the 1980s and 1990s, TEM- and SHV-types of ESBL were the most 
prevalent beta-lactamases, and particularly K. pneumoniae carrying these enzymes 
caused nosocomial outbreaks. Since the beginning of the new millennium, however, 
community onset infections with E. coli with CTX-M-types have been the 
dominating EPE worldwide (66, 69). Within two years after the introduction of the 
extended spectrum cephalosporins cefotaxime and ceftazidime, new ESBLs in E. 
coli and K. pneumoniae arose (70). The term extended-spectrum beta-lactamases 
was first coined in a review article from 1989 (71). Contrasting TEM and SHV, 
CTX-M-type beta-lactamases do not origin from mutations of plasmid mediated 
penicillinases. They originate from the chromosomal genes of the non-pathogenic 
commensal Kluyvera spp. and were mobilized by insertion sequences onto plasmids 
(72). CTX-M-type beta-lactamases were first described in E. coli strains isolated 
from a German patient in 1990, and soon many similar reports followed (73-76). 
The name CTX-M is an abbreviation of the beta-lactamase cefotaximase and refers 
to the great hydrolytic activity against cefotaxime, and the M denotes Munich, 
Germany, where it was first described (77).  
CTX-M-type beta-lactamases are transferred by plasmids and there are over 220 
different types known. They are characterized into five different clusters or subtypes 
depending on the amino acid sequences; CTX-M-1, CTX-M-2, CTX-M-8, CTX-M-
9 and CTX-M-25 (69). Early geographical hotspots for the emergence of CTX-M 
beta-lactamases were Central Europe, South America and Japan (78). 
The CTX-M-15 enzyme belongs to the subgroup CTX-M-1 and is the most globally 
spread enzyme, prevalent worldwide. It was first described in 2001, from patients 
hospitalized in New Delhi, India (73). Since then, the spread of CTX-M-15 has 
increased both in the community and in hospitals. 
5.1.4 Carbapenemases 
Soon after carbapenems became commercially available in hospitals in the second 
half of the 1980’s, reports of carbapenemases arose (79, 80). Carbapenem resistance 
can also arise as a result of ESBL or AmpC in combination with decreased 
permeability (porin loss) or increased efflux (80). Bacteria carrying such resistance 
are commonly multidrug-resistant, and few (if any) antibiotics are available for 
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treatment. Even though carbapenemases are clinically important and was actively 
sought for in my different projects, they were not the main focus of this thesis. 
5.2 The definition of ESBL-producing bacteria 
ESBLs are beta-lactamases produced by bacteria that hydrolyse the beta lactam-ring 
of extended spectrum cephalosporins, and thereby inactivating them (81). Typically, 
they degrade ceftriaxone, cefotaxime, ceftazidime and oximino-monobactam. In 
contrast, carbapenems, cephamycins and beta-lactamase inhibitors stay intact. Thus, 
clinical infections caused by ESBL-producing bacteria cannot be treated with 
extended-spectrum cephalosporins or monobactams, but carbapenems can be used 
successfully in most cases.  
Furthermore, the gene encoding resistance should according to the definition be 
transferrable between bacteria of the same or different species. In clinical routine 
diagnostics, this is not used as a criterion of ESBL as it requires sequencing 
methods, which is relatively expensive and time consuming. Instead, if a strain is 
resistant against one or more of the third generation cephalosporins and is positive 
in phenotypical and/or genetical beta-lactamase tests, it is characterized as ESBL-
producing (82). 
Internationally, ESBLs are generally characterized depending on which beta-
lactamase they exhibit, and usually the term ESBL is accompanied with the enzyme 
family; e.g. CTX-M-15 ESBL (83). In Sweden and Norway, ESBLs are 
characterized phenotypically into ESBLA and ESBLM based on how they are 
inhibited as defined by Giske et al. (84). This does not require sequencing of the 
bacteria, which is primarily used in research settings. In this thesis, the later Swedish 
nomenclature will be used. 
Classification according to ESBLA is based on phenotypical diagnostics; these 
strains are inhibited by clavulanic acid. Enterobacterales with ESBLM express 
resistance against cefoxitin. Cefoxitin is a second generation cephamycin, grouped 
with second-generation cephalosporins. Many Gram-negative bacteria have 
naturally occurring chromosomally encoded beta-lactamases. Klebsiella spp., 
Salmonella spp. and Proteus spp. do not, which is why phenotypical tests are 
sufficient to establish that they carry pAmpC. For all other species, genetic tests 
must be performed as well to differentiate between chromosomally or plasmid- 
encoded AmpC. This is displayed in detail in Figure 18 and 19.  
Thus, phenotypically characterizing E. coli as ESBLM does not distinguish between 
plasmid- or chromosomally encoded AmpC, which could lead to overreporting of 
ESBL isolates.  
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Many different bacteria can produce ESBL; clinically relevant ones include species 
within Enterobacterales, such as Proteus spp., Klebsiella spp., Salmonella spp., but 
also Acinetobacter spp. and Pseudomonas aeruginosa. Sometimes phenotypic 
ESBL/pAmpC is be found, but no known gene of ESBL/pAmpC is found when 
strains are sequenced (85). 
5.3 ESBL vs AmpC 
The first report of a plasmid-encoded AmpC came from South Korea in 1989, and 
was found in a strain of K. pneumoniae having caused a wound infection (86). From 
a clinical perspective, the difference between ESBL and AmpC is of academic 
nature. There is no evidence of difference in potency, virulence or clinical features 
between strains carrying these two groups of resistant determinants when comparing 
outcomes of invasive infections (87, 88). When comparing prevalence, ESBL 
outnumber AmpC by far and it is worth noting that strains can carry genes encoding 
both ESBL and AmpC resistance simultaneously. In this thesis, ESBL and AmpC 
will simply be referred to as ESBL. 
Generally, AmpC resistance can be characterized into three different groups (89). 
The historically most common type of AmpC resistance is the inducible resistance, 
but this only affects cephalosporins of the first and second generation. 
Here, two types of AmpC resistance are relevant. First, non-inducible (constitutive) 
chromosomally encoded resistance due to mutations, causing hyperproduction of 
AmpC. Secondly, plasmid encoded AmpC (pAmpC). While AmpC resistance in E. 
coli can be encoded both by chromosomes and plasmids, K. pneumoniae lacks 
chromosomal AmpC. There are 29 known genes encoding for pAmpC, divided into 
6 different families (90). Common AmpC enzymes include CMY, DHA and ACT. 
Clinical isolates carrying multiple pAmpC beta-lactamases have not yet been 
reported. 
5.4 Classification of beta-lactamases 
Beta-lactamases are commonly classified according to Ambler or Bush-Jacoby-
Medeiros (91, 92). Ambler’s classification is based on structural homology, whereas 
Bush-Jacoby-Medeiros is based on hydrolytic properties. In this thesis, Ambler’s 
classification from A through D based on amino acid sequence homology will be 
discussed in brief. Ambler’s classification is displayed in Table 1.  
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Table 1. Classification of beta-lactamases according to Ambler. 
 
 
Ambler class A enzymes is a heterogenous group of enzymes that generally are 
inhibited by beta-lactamase inhibitors such as clavulanic acid. SHV and TEM are 
notable examples of extended-spectrum beta-lactamases of this group.  
The majority of the class A ESBLs belong to the TEM-, SHV- or CTX-M- groups, 
and the genes coding for these enzymes are designated blaTEM, blaSHV and blaCTX-M, 
respectively. They are commonly found in, but not restricted to, E. coli and K. 
pneumoniae. The CTX-M-group is large and is today the most clinically important 
family of ESBL enzymes, prevalent all over the world. Other notable ESBLs are 
BES, GES-1, VEB and PER. Notable class A carbapenemases are KPC, SME and 
IMI. Class A enzymes are encoded on plasmids, chromosomes and integrons.  
Ambler class B enzymes consist of the metallo-beta-lactamases and generally 
confer resistance to penicillins, cephalosporins, carbapenems but not aztreonams. 
The blaMBL genes are located on chromosomes, plasmids and integrons. While the 
beta-lactamases of class A, C and D are serine beta-lactamases, class B beta-
lactamases are Zn2+-dependent in the beta-lactam hydrolysis. Therefore, metal-
chelating agents like ethylenediaminetetraacetic acid (EDTA) can inhibit this 
process (93). This is of relevance only in in vitro testing. 
Ambler class C AmpC beta-lactamases are usually encoded on the chromosome, but 
plasmid encoded AmpC (pAmpC) are becoming increasingly prevalent. AmpC 
beta-lactamases are inhibited by cloxacillin, oxacillin and aztreonam. Bacterial 
strains with AmpC beta-lactamases are usually resistant to penicillins, beta-
lactamase inhibitors, cephalosporins including cefoxitin but not carbapenems.  
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Ambler class D beta-lactamases are called oxacillinases (OXA). Usually, 
oxacillinases are encoded chromosomally and confer resistance to penicillins, 
cephalosporins and carbapenems. Class D beta-lactamases are inhibited in vitro by 
sodium chloride. Acinetobacter baumannii and Pseudomonas aeruginosa are 
examples of bacteria that frequently harbour oxacillinases (94).  
 
Figure 5. Examples of enzymes from each Ambler class. 
Class A SHV-2 beta-lactamase, class B IMP-1 beta-lactamase, class C E coli AmpC beta-lactamase, class D OXA-1 
beta-lactamase. The serine active sites are displayed in yellow for classes A, C and D. The two Zn2+ ions are shown 
in for class B. Reprinted with permission from author Robert A. Bonomo (93). 
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5.5 Mechanisms of beta-lactamases 
Simplified, the outer part of a Gram-negative bacterium consists of cytoplasmic 
membrane, periplasmic space and an outer membrane. The peptidoglycan layer is 
present in the periplasmic space and is relatively thin compared to that of Gram-
positive bacteria. 
 
Figure 6. Schematic presentation of a Gram-negative bacterial cell wall. 
As previously described, the transpeptidases responsible for peptidoglycan cross-
linking are the targets of beta-lactam antibiotics. Both beta-lactams and beta-
lactamases are likely evolutionary ancient, and have evolved in parallel during the 
competition for ecological niches throughout history; some beta-lactamases are 
estimated to be over 3 billion years old (95). Beta-lactamases are prone to evolve 
and single-nucleotide mutations can significantly alter the functionality (86). 
In Enterobacterales, several different mechanisms can inhibit the effect of beta-
lactam antibiotics. It is important to note that these mechanisms can occur 
simultaneously. In the presence of the selective pressure of beta-lactam antibiotics, 
bacteria with multiple mechanisms of resistance are favoured (95).  Below, 
a brief description of the four main resistance mechanism in Enterobacterales are 
presented. 
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I. Plasmid-mediated production of ESBLs.
In Enterobacterales, this is the most important mechanism of resistance. The 
antibiotic degrading enzymes produced are often encoded from plasmids of the 
cytoplasm, and excreted into the periplasm (64). ESBL enzymes hydrolyse the beta-
lactam ring, inactivating beta-lactam antibiotics such as penicillins and 
cephalosporins. 
Figure 7. Schematic presentation of antibiotic degrading enzymes. 
Note the ESBL, here displayed as a yellow scissor, hydrolysing the beta-lactam ring displayed in red. 
Importantly, plasmids carrying ESBL-genes often carry genes encoding resistance 
to fluoroquinolones, aminoglycosides, trimethoprim-sulfamethoxazole and other 
antibiotic classes simultaneously. ESBL-producing bacteria are therefore 
commonly referred to as multidrug-resistant bacteria. Treatment with any of these 
antimicrobials may facilitate further spread of ESBL. Below, important mechanisms 
of resistance to beta-lactam antibiotics other than beta-lactamases are discussed in 
brief. 
II. Reduced permeability due to decreased expressions of outer membrane proteins
(OMPs).
Beta-lactam antibiotics access the periplasmic space thorough OMPs, and loss of 
OMPs can lead to reduced permeability. This can be the result of mutations in 
bacterial genes encoding for OMPs (86). This prevents the beta-lactam antibiotics 
from entering the bacterium. This resistance mechanism can be effective for several 
beta-lactams and some Enterobacteriales exhibits resistance to carbapenems in this 
manner  
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Figure 8. Schematic presentation of reduced permeability. 
III. Upregulation of efflux pumps. 
Substrates from the cytoplasm and/or the periplasmatic space are actively 
transported out from the bacteria. This naturally reduces the amount of beta-lactam 
antibiotics in the periplasmatic space. This is also an important mechanism of the 
bacteria in conferring resistance to multiple antibiotic classes. 
 
Figure 9. Schematic presentation of upregulated efflux pumps. 
IV. Alterations in PBP, that render them with reduced binding. This is an important 
mechanism of antibiotic resistance in mostly Gram-positive bacteria, of which 
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methicillin resistance in Staphylococcus aureus is a notable example. Interestingly, 
the PBP seems to be the ancestors to beta-lactamases (96). PBPs are clinically 
important but will not, however, be further covered in this thesis. 
5.6 Horizontal gene transfer 
The core of horizontal gene transfer is the acquisition of genetic elements from other 
bacteria. There are three ways in which DNA can be transferred between cells; 
transformation, transduction and conjugation (97). In this thesis, conjugation and 
bacterial plasmids that promotes this process will be discussed in brief.  
In the bacterial cell, there are two structures containing genetic material. Most 
bacterial species have one, circular chromosome in the cytoplasm. Plasmids are 
circular units of double-stranded DNA, that can be transferred from one bacterium 
to another of the same or different species (98). 
Figure 10. Schematic presentation of the genetic material of bacteria. 
Plasmids and chromosomal DNA exist and replicate separately from each other. 
Plasmids vary in size; some carry 2 or 3 genes, others more than 400. Many plasmids 
are conjugative plasmids, they carry DNA to enable cell to cell DNA transfer, 
particularly their own transfer. Plasmids may carry antimicrobial resistance genes, 
and virulence factors such as aerobactin and other metabolic functions (42).  
Examples of clinically relevant plasmids conferring ESBL-resistance include IncI1, 
IncK, IncF and IncN (99). In E. coli, plasmids of the IncF family are almost 
exclusively responsible for the successful global dissemination of the blaCTX-M-gene 
(100). 
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5.7 Conjugation  
The process of conjugation needs the involvement of either a plasmid or a 
transposon. Transposons are mobile genetic elements, carrying resistance genes, 
able to transfer between bacteria.  
 
Figure 11. Schematic presentation of conjugation. 
The conjugation pilus (plural, pili) draws the two bacterial cells close. The double-stranded DNA of the plasmid is 
copied into the cytoplasm of the recipient bacterial cell. The recipient bacterial cell will eventually become a donor 
bacterial cell, with its own plasmid and conjugation pilus. 
In short, transformation is the process where the DNA of a bacterial cell is released, 
fragmented and taken up and incorporated into the genome of a different bacterial 
cell. Transduction involves bacterial lysis, the release of fragmented DNA which is 
incorporated into the genome of other bacteria by bacteriophages (97). Additionally, 
integrons of gene cassettes are helpful tools for bacteria in acquiring resistance 
genes.   
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5.8 Outer membrane vesicles (OMVs) 
Another way in which bacteria can interact with the surroundings is to produce 
OMVs. OMVs could be regarded bacterial escape pods, but the functions of these 
OMVs are versatile. One of many purposes is to transport resistance and virulence 
genes out of the cells (101, 102). Recently, it has been demonstrated that EPE can 
spread the blaCTX-M-15 gene by releasing OMVs (103). 
 
Figure 12. Schematic presentation of the formation of OMVs. 
As seen above, plasmids can reside in the periplasmatic space (a). A circular form of the outer membrane is detached 
to form the outer membrane vesicle (b). It could be regarded as a bacterial “escape pod”, filled with genetic material 
ensuring further existence and proliferation of bacterial DNA (c).  
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As a conclusion, using these mechanisms of horizontal gene transfer, the entire 
global bacterial gene pool is potentially available as a source for bacteria to gather 
resistance genes. This is a logic outcome of Darwin’s theory of evolution by means 
of natural selection; the more resistance genes, the more likely to survive when 
exposed to antibiotics. It however also tangles the evolutionary tree, since not all 
genetic traits in bacteria are inherited from “parent” strains. 
5.9 Fitness cost 
Is there a downside of carrying resistance genes? If not, why are not all bacteria 
multidrug resistant? The dominating theory is that with increased carriage of 
resistance genes comes  reduced bacterial fitness. In the absence of antibiotics, in 
vitro models have shown that the acquisition of resistance genes is associated with 
fitness costs (104). Once a plasmid is acquired by a bacterial cell, 
transcription/translation machinery is seized in order to enable plasmid gene 
expression. This happens on cost of essential chromosome transcription/translation, 
resulting in changed cell protein expression and overall loss of fitness. Thus, a 
bacterial cell compensatory mechanism is plasmid degradation, to maintain the 
essential chromosome transcription/translation (27). However, the issue of bacterial 
fitness is complex, and in a small number of clones, compensatory mutations can 
occur, enabling the continued expression of plasmid gene expression without a loss 
of fitness. Although this mechanism is not fully understood, this is a theory behind 
the successful dissemination of ESBL-producing E. coli ST131, among other genes 
carrying the ESBL genotype blaCTX-M-15. 
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6 Epidemiology  
6.1 EPE in Skåne 
Compared to the rest of the world, the prevalence of EPE in clinical cultures in 
Skåne is low and comparable to other parts of Sweden. However, the prevalence of 
faecal carriage of EPE in individuals in Skåne is unknown, as studies investigating 
the prevalence in Skåne are rare. One small study investigating the faecal carriage 
in the community found that in 2008 and 2010, the prevalence (obtained at primary 
health care units) was 2.1% and 3%, respectively. The rate of faecal carriage of the 
patients of a University hospital in Skåne in 2008 and 2010 were 1.8% and 6.8%, 
respectively (105). Another study compared the rate of faecal EPE carriage in 
elderly people living at nursing homes, 11%, with elderly living at their own homes, 
8.7%, and found no statistical difference (106). 
Regional epidemiological data from the Clinical Microbiology laboratory of Skåne 
University hospital is available (107). One should be cautious to draw any 
conclusions when the actual numbers are low, but the data shows that the trend over 
these 11 years is a (slowly) rising prevalence of ESBL in clinical cultures. 
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Figure 13. EPE in Skåne, Sweden 2011-2019. 
The number of patients with a positive culture for an ESBL-producing bacterium. Green stacks show positive 
screening samples of ESBL, obtained from faeces or rectum. The blue stacks represent positive clinical samples of 
ESBL; from urine, blood, skin/soft tissue, airway, cervix or other. It is important to note that all patients with a history of 
receiving in patient health care in a foreign country during the last 6 months are screening for ESBL-producing 
bacteria. These patient samples constitute the bulk of the green stacks. Regional epidemiological data from the 
Clinical Microbiology laboratory of Skåne University hospital (107). 
Between the years 2011 and 2019, the incidence of invasive (bacteremia) ESBL-
producing E. coli and K. pneumoniae increased from 4.7% and 2.8% to 7.2 % and 
4.7%, respectively.  
Table 2. Invasive ESBL-producing E. coli and K. pneumoniae in Skåne, Sweden 2011-2019. 
Year 
Invasive 
E. coli 
ESBL-producing E. 
coli 
ESBL, 
(%) 
Invasive K. 
pneumoniae 
ESBL-producing K. 
pneumoniae 
ESBL 
(%) 
2011 1045 49 4.7 215 6 2.8 
2012 1183 71 6 187 9 4.8 
2013 1211 79 6.5 200 5 2.5 
2014 1271 85 6.7 209 11 5.3 
2015 1365 93 6.8 214 6 2.8 
2016 1332 104 7.8 265 14 5.3 
2017 1422 97 6.8 242 12 5 
2018 1362 104 7.6 271 13 4.8 
2019 1470 106 7.2 258 12 4.7 
The actual numbers are low, but the trend is a rising prevalence of ESBL-producing strains. Regional epidemiological 
data from the Clinical Microbiology laboratory of Skåne University hospital (107).  
In Skåne, invasive infections with carbapenem-resistant E. coli or K. pneumoniae 
are extremely rare. During the 9 years between 2011-2019, invasive infections with 
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carbapenem-resistant E. coli and K. pneumoniae occurred in 5 and 2 patients, 
respectively. Interestingly, during these years, the invasive carbapenem-resistant E. 
coli or K. pneumoniae cases in Skåne made up 33 % of all cases in Sweden. 
Table 3. Invasive carbapenem resistant E. coli and K. pneumoniae in Skåne, Sweden 2011-2019. 
Regional epidemiological data from the Clinical Microbiology laboratory of Skåne University hospital (107).  
For both E. coli and K. pneumoniae, invasive ESBL-producing strains are often 
resistant to aminoglycosides (data available for gentamicin and tobramycin, ~40-60 
%), ciprofloxacin (~60%) and trimethoprim-sulfamethoxazole (~60-85%). 
In Skåne, as well as the majority of other counties in Sweden, all patients with a 
history of receiving health care (admitted to hospital or advance outpatient care) in 
a country outside of the Nordic countries during the previous 6 months are screened 
for MRSA, VRE and EPE at admission or prior to admission. 
Additionally, patients are screened if they have been in highly endemic areas (Asia, 
Africa, the Middle East, South or Central America) for more than two months 
alternatively present with a skin wound and/or soft tissue infection that arose during 
or adjacent to the trip.  
These cultures are obtained from vestibulum nasi, throat, perineum and rectum. 
When relevant, additional cultures are obtained from urine catheters, central venous 
catheters, eczema, stomia and from clinical wounds.  
6.2 EPE in Sweden 
The largest nationwide study investigating the prevalence of community carriage of 
EPE in Sweden gathered data between November 2012 and December 2013. It 
found an asymptomatic faecal carriage rate of 4.7% in healthy Swedes (58). When 
comparing these strains with invasive EPE strains using molecular methods, the 
authors found less multidrug resistance and lower pathogenicity of the faecal strains. 
Year Invasive carbapenem resistant E. coli Invasive carbapenem resistant K. pneumoniae 
2011 0 0 
2012 1 1 
2013 1 0 
2014 0 0 
2015 1 0 
2016 1 0 
2017 0 0 
2018 1 1 
2019 0 0 
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The rate of community carriage was slightly higher compared to other, smaller 
studies conducted in Sweden during the same time (23, 105, 108).  
The faecal carriage of EPE in toddlers at preschools has been investigated in 
Uppsala, Sweden, and published in 2011 and 2018. The rate of faecal carriage of 
EPE increased rapidly between the years 2011 and 2018, from 2.9% to 20.1%, 
respectively (109, 110). 
Epidemiological data on the prevalence of invasive infections of EPE is available 
from the European Centre for Disease Prevention and Control (ECDC), through the 
European Antimicrobial Resistance Surveillance System Network (EARS-Net) 
(111). There is no data from intestinal colonization of EPE. Between the years 2011 
and 2018, the incidence of invasive ESBL-producing E. coli and K. pneumoniae in 
Sweden more than doubled; it increased from 3.6 and 2.3% to 8.3  and 5.5%, 
respectively.  
Table 4. Invasive ESBL-producing E. coli and K. pneumoniae in Sweden 2011-2018. 
Year Invasive E. coli ESBL-producing E. coli ESBL (%) 
Invasive  
K. pneumoniae ESBL-producing K. pneumoniae ESBL (%) 
2011 5102  3.6 943 22 2.3 
2012 5537  4.5 977 28 2.9 
2013 7532  5.2 1300 47 3.6 
2014 6546  5.6 1000 45 4.5 
2015 5995 6.2 1001 33 3.3 
2016 6958  8.3 1537 75 4.9 
2017 5790  7.4 1034 58 5.6 
2018 5390  8.3 1089 60 5.5 
Data from European Antimicrobial Resistance Surveillance System Network (EARS-Net) (111). When this thesis was 
written, the latest data available was for 2018. 
During these years, invasive infections caused by carbapenem-resistant E. coli or K. 
pneumoniae were rare events in Sweden. 
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Table 5. Incidence of invasive carbapenem-resistant E. coli and K. pneumoniae in Sweden 2011-2018. 
Year Invasive carbapenem resistant E. coli Invasive carbapenem resistant K. pneumoniae 
2011 0 0 
2012 1 1 
2013 2 0 
2014 0 0 
2015 4 0 
2016 6 2 
2017 1 1 
2018 1 2 
Data from European Antimicrobial Resistance Surveillance System Network (EARS-Net) (111). When this thesis was 
written, the latest data available was for 2018. 
6.3 EPE in the rest of the world  
During the past two decades, numerous studies investigating the prevalence of 
faecal colonization of EPE in healthcare settings and the community have been 
published, in both healthy and symptomatic individuals. For many reasons, the 
results of these should be interpreted with caution. The definition of what constitutes 
EPE differs between studies. Diverse laboratory methodology of how EPE is 
detected has been used. Most notably, they vary in study design, size and target 
population, resulting in questionable external validity. Not one study can be 
generalized to reflect the EPE prevalence of the inhabitants of the whole country. 
By early 2000, the CTX-M-enzymes had replaced the hitherto dominating beta-
lactamases TEM and SHV. Since then, the CTX-M-type of beta-lactamases have 
emerged as the most common ESBLs in both developed and developing countries 
(112). As previously stated, there are several hundred different CTX-M-types, but 
the most common are CTX-M-15, CTX-M-14 and CTX-M-27 (100, 112). CTX-M-
14 dominates in China, Japan, South Korea, Spain and south-east Asia. In South 
America and Israel, CTX-M-2-type beta-lactamases are important. In the rest of the 
world, however, CTX-M-15 is the most prevalent CTX-M-enzyme (72, 78).  
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Figure 14. Estimated rates of ESBL producers among E. coli clinical isolates. 
Data from 2014, published by the World Health Organization. Grey indicate countries with insufficient data. Reprinted 
with permission from author Yohei Doi (112). 
As previously stated, the successful dissemination of CTX-M-15 is partly attributed 
to the clone ST131, including its subclone H30-Rx (113). The worldwide spread is 
attributed to the expression of certain virulence factors, resistance genes and the 
ability to colonize and persist in the intestines. Depending on geographic region, the 
proportion of ST131 in clinical human E. coli isolates range from 12.5 to nearly 
30% (114). 
In a review article on carriage of class A ESBL in healthy individuals, the pooled 
prevalence, when accounting for 66 worldwide prevalence studies, was estimated to 
be 14%, with an annual increasing trend of 5% (115).  
6.3.1 Incidence of invasive EPE in Europe. 
In Europe, data for 2018 obtained from EARS-Net, show the highest rates of 
cephalosporin-resistant invasive E. coli for Bulgaria (38.7%), Cyprus (37.1%), 
Slovakia (28.1%) and Italia (28.7). In contrast, Norway (6.8%), Netherlands (7.3%), 
Finland (7.6%) and Denmark (7.7%) reported the lowest rates. For invasive K. 
pneumoniae, the highest rates of cephalosporin-resistant strains were seen for 
Bulgaria (77.7), Greece (70.7%), Poland 64.6 (%) and Romania (61.4%). Lowest 
rates were reported from Finland (4.5%), Sweden (5.5%), Norway (7.5%) and 
Denmark (6.5%) (111). 
53 
The rates of carbapenem-resistant invasive E. coli were low in 2018; Cyprus (2%), 
Greece (1%) and Bulgaria (1.4%) had the highest rates. For carbapenem-resistant 
invasive K. pneumonia, however, the percentages were significantly higher; Greece 
(63.9%), Romania (29.5%), Italy (26.8%) and, finally, Cyprus (21.8%). 
6.3.2 Increased prevalence of EPE faecal carriage in Europe 
Community carriage of EPE in healthy individuals was first reported in 2003 from 
Spain and Poland (116, 117). Since then, European countries have reported rising 
prevalence of community carriage of primarily CTX-M-15 EPE strains, except for 
Spain where CTX-M-14 and CTX-M-9 have been the dominating beta-lactamases 
found in EPE isolates (118). In eastern Europe, the main ESBL beta-lactamase has 
been CTX-M-3 (119). 
In the Netherlands, a country with relatively low EPE resistance detected in clinical 
isolates, community carriage of EPE in 2011and 2016 were 8.6% and 4.5 %, 
respectively (120, 121). Most studies conducted in nursing homes in Europe show 
higher rates. Elderly people living in long-term care facilities found EPE carriage 
rates of 14.5%, 11.3% and 40.5% in the Netherlands, Belgium and Northern Ireland, 
respectively (122, 123). The rate of EPE faecal carriage in patients admitted to 
French hospitals were 17.7% and 17.0% in 2014 and 2016, respectively, and a study 
on healthy children at French Day care centres found an EPE prevalence of 6,7% 
(124-126). The prevalence of EPE in healthy individuals was found to be 5.8%, 
2.0% and 3.0% in Switzerland, Portugal and Hungary, respectively (127-129). A 
recent study from hospitalized patients in London reported an EPE prevalence of 
9.0 % (130). In Norway, patients with diarrhoea had an EPE prevalence of 15.8% 
(131). One study identified ESBL-producing E. coli in Latvia, Germany, Finland, 
Sweden, Poland and Russia to be 1.6%, 4.7%, 6.6%, 8.0% and 23.2%, respectively. 
ESBL-producing K. pneumoniae was only detected in Sweden, Finland and Russia 
in rates of 0.3%, 1.1% and 2.0%, respectively (132). A relatively large study from 
Netherlands found an EPE colonization of 5% in the general population (133). 
The pooled prevalence of class A ESBL in healthy individuals was estimated to 4% 
in the European population in general (115). 
6.3.3 The prevalence of EPE faecal carriage in Asia is higher 
compared to Europe 
Asia is commonly regarded a hotspot for multidrug resistant bacteria; the highest 
reported community carriage prevalence of EPE intestinal carriage in the world 
origin from Asia. In stool samples obtained in China between 2013-2014, 73.9 % of 
individuals tested carried Enterobacterales with a CTX-M-gene (134). 
Furthermore, studies from Thailand report EPE intestinal colonization rates of 
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61.7% and 69.3 %, respectively (135, 136). One study from Nepal in 2019 reported 
a rate of 68.9% of EPE carriage of healthy individuals (137). However, not all 
countries in Asia report rates of this magnitude. In Taiwan, only 1.9% of 
asymptomatic outpatients were colonized by EPE in 2017; in Japan 6.4% of healthy 
volunteers were colonized (138, 139). In Korean patients screened for ESBL-
producing K. pneumoniae when admitted to an ICU, 6.4% were colonized (140). 
However, when screened for EPE in general in similar settings in Korea, 
colonization rates were higher; 28.2% and 42.5%, with a prevalence in healthy 
individuals of 20.3% (141, 142). A recent study on healthy adults from Taiwan 
found an EPE prevalence of 41.4% (143). 
In Nepal, prevalence of EPE in children with diarrhoea rose from 1.5% in 2001 to 
35% in 2016 (144). In Cambodia, the rate of EPE colonization among healthy 
individuals was 20% in 2011, with a variation between 5-62% when comparing 10 
different villages (145). Prevalence studies from China report rates of EPE 
colonization in healthy individuals between 30.5-73.9%, 46.9% in nursing homes 
(134, 146-149). 
A small study out of Lebanon conducted in 2013 reported an EPE carriage rate of 
healthy children of nearly 25% (150). In India, reports of EPE colonization rates of 
healthy individuals are scarce and most reports are on international travellers 
returning from India. One study, however, report a carriage rate of cephalosporin-
resistant Enterobacterales of 61.4% in healthy Indian individuals (151). A recently 
published study from Pakistan reported an EPE prevalence of 43% among healthy 
children (152). 
6.3.4 EPE faecal carriage in North America 
Data of EPE colonization in healthy individuals from the USA is surprisingly 
limited. In a survey of hospitalized patients in 2007-2009, the EPE colonization rate 
was 2.6% and another report conducted between 2000 and 2005 saw an increase of 
EPE colonization from 1.3 to 3.2 % (153, 154). In Californian children under 15 
years of age, EPE colonization rate was 3.5%, where the highest prevalence (5.9%) 
was seen in the subgroup of children below two years of age (155). In a study 
performed in Pennsylvanian long-term care facilities in 2006-2008, 3.4 % of the 
elderly were colonized with EPE (156). In California, a 17% prevalence of intestinal 
EPE carriage was found in 2015, and a recent study conducted in the same state 
between 2016-2017 found a prevalence of 38% in long-term care facilities and 34% 
and nursing homes (157, 158). 
In two studies performed on international travellers in 2012 and 2013, one out of 
sixty and none of fifty-eight participants, respectively, carried EPE before travelling 
(159, 160).  
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A small study from 2010 performed in Canada found an EPE colonization rate of 
healthy individuals of 9%, however only 67 individuals were included (161). 
In Mexico between 2014 and 2015, 17.5 % of cancer patients who were screened 
prior to elective surgery were EPE positive (162). 
6.3.5 EPE faecal carriage in South America 
Recent studies from South America investigating EPE colonization in humans are 
uncommon. An older study investigating EPE colonization in children in Bolivia 
and Peru showed an increase from 0.1% in 2002 to 1.7% in 2005 (163). Another 
study in children of Bolivia showed an EPE rate of 12.4 % in 2011 (164). In 
Argentina, cultures of outpatients with gastrointestinal complaints revealed an EPE 
colonization rate of 26.8% (165). 
6.3.6 EPE faecal carriage in Oceania 
In a study conducted between 2008-2009 in Australia on 106 international 
travellers, 2 % were EPE colonized in the pre-travel stool sample (166). A study on 
patients admitted to the ICU in Melbourne in 2011 found an EPE prevalence of 
13.9% (167). In the same city, the prevalence of EPE in three nursing homes was 
12%, and for patients undergoing transrectal prostate biopsy an EPE prevalence of 
7 % was reported (168, 169). 
6.3.7 EPE faecal carriage in Africa 
In northern Africa, intestinal carriage rates of EPE have been reported from Tunisia 
(7.3 %) and Egypt (63.6%). In sub-Saharan Africa, rates have been described for 
Senegal (10.0%) and Niger (30.9%) (55). During the last years, community carriage 
in Africa has been studied more extensively, primarily in children. A study on 
children in Tanzania, both hospitalized and in the community, showed EPE rates of 
50.4% and 11.6%, respectively. Interestingly, K. pneumoniae dominated in 
prevalence rather than E. coli (170). Additional studies from Tanzania show EPE 
faecal carriage of 31.8% in children, and 16.5% and 60% in adults, respectively 
(171-173). Furthermore, a small study of children in Central African Republic 
showed a rate or EPE carriage of 59% (174). In children of Guinea-Bissau and Togo, 
rates of positive EPE in stool samples were 32.6% and 60.5%, respectively (175, 
176). In Chad, the prevalence of intestinal EPE carriage was found to be 38% in 
healthy volunteers and  51 % in hospitalized patients (177). 
In south Africa, the prevalence of EPE colonization was 22.7% in one study (178). 
The pooled prevalence of class A ESBL in healthy individuals was estimated to 22% 
in Africa in 2016 (115). 

57 
7 Devil in a new dress; the 
carbapenemases. 
Carbapenemases are beta-lactamases able to hydrolyze penicillins, cephalosporins, 
aztreonam and carbapenems. Clinically relevant carbapenem antibiotics are 
imipenem, meropenem, ertapenem and doripenem. Carbapenemases rose in 
prevalence in clinical isolates after the introduction of carbapenem antibiotics in 
health care in the late 1990s. Invasive infections with strains resistant to 
carbapenems are increasing in prevalence and are associated with high morbidity 
and mortality, with mortality rates of some carbapenemase-producing bacteria up to 
50% (179). Carbapenemases belong to Ambler classification system class A, B and 
D. In parallel with ESBLs, carbapenemases are hydrolyzing enzymes, but bacteria 
frequently carry other resistance mechanisms such as production of efflux pumps 
and porin mutation or loss (180). Bacteria carrying carbapenemases also frequently 
carry genes encoding for ESBLs, and some isolates carry multiple carbapenemases 
(86).  
Clinically, therapeutic options to treat carbapenem-resistant infections include 
colistin, fosfomycin, tigecycline and aminoglycosides, but resistance has been 
reported for all of these antibiotics. Some strains are resistant to all commercially 
available antibiotics investigated (181). For patients with invasive infections of 
strains resistant to carbapenems, a combination treatment of at least two susceptible 
antibiotics is generally recommended (180). Novel promising agents potentially 
becoming available commercially in the near future are plazomicin, 
meropenem/vaborbactam, eravacycline and cefiderocol, with activity against many 
carbapenemases occurring at the present time (180, 182-184). 
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8 Probiotics 
Probiotics are defined as living microbial food supplements that offer a health 
promoting benefit on the host when ingested in adequate amounts (185). Probiotics 
have surfaced as an aid to reverse a dysbiosis of the intestines. They are regarded 
safe, although it involves the intake of an enormous quantity of live bacteria (186, 
187). There is a vast number of  different probiotics available, many of which are 
sold over the counter. Some contain only one single probiotic bacterium, some have 
multiple species. The fungus Saccharomyces boulardii is regarded a probiotic. The 
use of probiotics has been popularized during recent years, and there are data of 
clinical effects on patients. In clinical randomized controlled trials, probiotics 
reduced gastrointestinal symptoms in patients with inflammatory bowel disease 
(188-190). 
In a study from India, probiotics given together with fructooligosaccaride reduced 
the incidence of death and sepsis in new-borns compared to placebo (191). 
Probiotics have shown effect in treating antibiotic associated diarrhoea, and several 
RCTs have shown benefit in a variety of gastrointestinal diseases including risk of 
developing C. Difficile infection (192, 193).  
Probiotics have been proposed as therapy to reduce carriage of multidrug resistant 
bacteria, but most existing clinical studies are inconclusive and have conflicting 
results (191, 194-197). The proposed mechanism is by competitive exclusion, and 
in vitro experiments of several Lactobacilli have shown inhibitory effect on the 
growth of ESBL-producing E. coli (198). In Paper III, we used Vivomixx®, which 
contain Lactobacillus plantarum, L. paracasai, L. acidophilus, L. 
delbrueckii ssp. bulgaricus, Bifidobacterium longum, B. infantis, B. 
breve and Streptococcus thermophiles. Vivomixx® is available over the counter and 
was previously known as VSL#3. 
 Probiotics act through four main mechanisms; i) production of acids and toxins 
which lower the intestinal pH and inhibit pathogenic bacteria; ii)  colonization of 
the gut which prevents adherence of pathogenic bacteria; iii) stimulation of the 
immune system, and, finally, iv) by strengthening the defence mechanism of the 
mucosa (199-202).  
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There are several challenges associated with probiotic therapy. They are generally 
not inexpensive. Optimal dosage is unknown. Also, there could be a problem with 
product sustainability; generally probiotic bacteria are unable to survive for longer 
periods, especially at room temperature. Furthermore, another problem is 
persistence in the intestines. The perseverance of probiotics in the intestines is only 
a few days (188). Thus, once the ingestion of probiotics is terminated, resident 
bacteria of the microbiota may outcompete the probiotics strains. 
The dose and duration of administration of Vivomixx® used in Paper III, was 
discussed with its inventor, professor De Simone. This dose is identical to what had 
been used safely and tolerably in previous studies (190). 
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9 A brief and simplified account of 
the immune response to microbes 
The healthy human immune system is an immensely complex system. It is divided 
into two key components, the innate and the adaptive immune system. The innate 
immune system is evolutionary older and shared with plants, fungi and other less 
advanced organisms. It is described as the first line of defence against pathogens; it 
is rapid and non-specific. It involves physical and chemical barriers, pattern-
recognition receptors and cell-mediated components (203). 
The cells of the adaptive immune system are capable of immune memory; once 
stimulated, they can persist for months or years to become reactivated once an 
antigen reoccurs. It reacts slower than the innate immune system but is highly 
specific. T- and B-lymphocytes form the backbone of the adaptive immune system. 
For a long time, the adaptive and the innate immune system have been regarded as 
two entirely separate systems. Recently, however, the connection and interplay 
between the two has been mapped (204). Natural killer (NK) cells, for instance, have 
long been classified as cells of the innate immune system. Recent research consider 
them to be a link between the adaptive and the innate immune system, sharing 
common features of both systems (205). 
B-lymphocytes, or B- cells, express B cell receptors on their cell membrane which 
allow the B-cell to bind to a specific antigen. This activates the B-cells and triggers 
antibody production. Immunoglobulin G the most prevalent type of antibody in the 
human body and represent 10-20% of plasma proteins (206).  
While it is undetermined if protective and detectable antibodies are produced in 
response to colonization with Enterobacterales, invasive infections in humans, 
however, give rise to an increased antibody response compared to controls (207, 
208).  
Peyer’s patches and mesenteric lymph nodes are involved in the innate immune 
response against bacteria entering the host through the intestinal mucosa. Also, the 
adaptive immune response plays an important role in this defence. Individuals 
immunized with Salmonella Typhi vaccine develop substantial levels of IgG and 
IgA targeting S. Typhi (209). Apart from serum produced IgG and IgM, mucosal 
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production of IgA (as well as in serum) is a major component of adaptive immune 
response against bacterial enteritis, including C. difficile (210). 
Oral therapy with chicken antibodies (IgY), where hens were immunized with 
epitopes from EPE, has been proposed as a way to achieve eradication of intestinal 
carriage of EPE (211). Recently, monoclonal antibodies specifically reacting to 
CTX-M enzymes in Gram-negative bacteria have been described (212). 
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10 Gaps of knowledge  
Although refined clinical and laboratory methods increase our knowledge of EPE, 
there are several unanswered questions regarding EPE in general and intestinal 
colonization of EPE in particular. The impact, consequences and host response of 
EPE colonization and infections needs of further research. 
10.1 Risk factors for acquisition of EPE  
Several risk factors for EPE acquisition are known, of which travel to high-endemic 
countries, antibiotic treatment are most prominent (130). For community carriage 
of EPE, one study associated a gut microbiota composition of the phylum 
Proteobacteria and the family Enterobacteriaceae, as well as travel to Southeast 
Asia in the past year (143) to EPE colonization. Another study identified vegetarians 
of significantly higher risk of EPE colonization compared to non-vegetarians (213). 
A relatively large Dutch study identified risk factors related to travel and hygiene, 
and another Dutch study found seasonal variances in intestinal EPE colonization, 
with highest prevalence in August and September (133, 214). 
Furthermore, risk factors for EPE carriage and infections of hospitalized patients 
have been studied. Sequencing of EPE isolates found in food and livestock revealed 
that they differ from invasive EPE strains found in hospitalized humans, suggesting 
that the food chain may not be a central route of acquisition of EPE in humans (215). 
The predominant route of EPE transmission seems to be person-to-person contact, 
and other sources such as contact with farm and companion animals, environmental 
sources and food are recognized to a lesser extent (216). Within-household 
transmission of EPE is regarded a plausible source, along with other elements, of 
the extensively dissemination of EPE in the community (217).  
A recent multi-centre study identified antibiotic therapy (hazard ratio 2.38), spring 
season and old age as independent risk factors of acquiring EPE during 
hospitalization, and the risk was highest for monotherapy with a cephalosporin 
(218). This risk could be affected by infection prevention measures and vary in low- 
and high endemic setting. 
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Several scores, such as the Stockholm and the Utrecht score, has been proposed to 
predict the risk of an invasive EPE infection, based on risk factors. The former 
identified a recent (particularly < 3 months) EPE positive faecal culture, recent 
prostate biopsy and healthcare abroad (219). Another study from the same group 
identified, other than previous antibiotic therapy, urological and immunological 
disorders, haematological malignancy, solid tumours and diabetes as risk factors of 
blood stream infection by EPE in a large, population-based study (220). 
The Utrecht score is comprised of two prediction rules for EPE, one for community 
onset and one for hospital onset suspected invasive EPE infections, which was 
recently validated in an international multi-centre prospective cohort study (221). It 
takes into account, among other factors, recent antibiotic used, immune status and 
suspected source of source of infection. 
It has been well established that traveling to areas where EPE colonization is 
endemic is a risk factor for EPE acquisition. However, the situation is potentially 
quite dynamic as awareness increases, travel patterns change, endemic situations 
and clonotypes may fluctuate. Furthermore, in certain areas of the world the 
prevalence carbapenemase-producing Enterobacterales (CPE) is increasing, but the 
rate of community spread is largely unknown. In Skåne, a study on EPE colonization 
in individuals with traveller’s diarrhoea highlighted the risk of EPE acquisition 
during international travel and informed on differential risks for different 
destinations (21). However, these data are now ten years old, and renewed 
information is needed to assess details on influx of EPE from international 
travellers, especially regarding what clones dominate and if CPE strains occur.  
What is the pathogenicity of these strains? What type of E. coli are they; commensal 
strains, intestinal pathogenic or ExPEC? What is the susceptibility of these strain to 
our available antibiotics? 
In conclusion, the current knowledge of transmission routes is incomplete, and more 
studies are needed regarding EPE and the risk of spillover; zoonotic infections with 
pandemic potential. 
Could EPE spread between companion animals within the same household? Could 
EPE spread between companion animals and humans of the same household? Is the 
microbiome protective against EPE- in line with colonization resistance?  
10.2 Prevalence of EPE  
The development and dissemination of resistance in Enterobacterales is complex 
and rapidly changing. EPE in clinical cultures are continuously monitored and 
reported by most countries, although scarce resources, surveillance quality 
variations and unwillingness to report information make global data incomplete. 
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Several smaller studies worldwide, as reported above, report the prevalence of 
intestinal colonization of EPE. However, they are quickly outdated and rely upon 
the interest and scientist or governmental bodies to perform repeated surveillance 
studies and share data. Ideally, global updated data of EPE colonization should be 
gathered and shared in an easily accessible data bank. 
Furthermore, the prevalence of EPE in the environment, in foodstuffs and in 
different animals is underexplored. In Sweden, the detection of EPE in clinical 
cultures of companion animals such as dogs is rare. However, one must remember 
the ease of which cutting edge diagnostical methods are available for humans in 
countries with resources. This is seldom the case for the care of companion animals, 
even in industrialized countries. At veterinary clinics, in-house microbiological 
analyses are largely unavailable. Even at the largest veterinary hospitals in Sweden, 
advanced microbiological analyses such as blood cultures, MAST-test etc are not 
readily accessible as diagnostic tools. The presence of ESBL is generally 
determined at the National Veterinary Institute of Sweden, in Uppsala, which 
gathers and reports data on e.g. EPE prevalence. However, many clinics use other 
private laboratories and data from the National Veterinary Institute of Sweden is 
therefore not representable as a measurement of EPE incidence in Sweden. Thus, 
there is need for data on EPE prevalence in companion animals. Additionally, EPE 
in farm animals, foodstuffs, sewage plants and in the environment needs to be 
further explored. 
 
Table 6. Number of clinical isolates of different bacterial species of Enterobacterales, producing ESBLA or ESBLM from 
companion animals and horses, 2008-2018. 
 
Reproduced from Swedres-Svarm 2018 (222).  
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10.3 Duration of colonization and risk factors for 
prolonged persistence 
As of date, it is unknown if successful decolonization of EPE can be achieved. While 
multiple travel studies report the spontaneous loss of intestinal colonization of EPE, 
it unknown if this represent perpetual loss of EPE or reflects poor sensitivity of EPE 
faecal samples (223, 224). Small numbers of EPE in the intestines could be difficult 
to detect with current tools of diagnostics. Several questions follows. What 
determines the duration of colonization? Are there specific bacterial characteristics, 
patient characteristics, environmental factors or a combination of different factors? 
If EPE is undetected by available culture methods, but still are colonizing the 
intestines in small amounts, is there still a risk for infection or person-to person 
transmission from them?? Could they cause severe disease? Could a patient, once 
proven colonized with EPE, ever be classified as decolonized of EPE? Should the 
EPE always be considered when initiating empirical clinical treatment? If the gut 
flora has returned to an equilibrium state- what happens if it is provoked with 
antibiotics? Would this lead to selection of EPE resurgence and subsequent 
increased risk for infection? 
In this field of research, there is absence of studies on how to predict prolonged EPE 
colonization, which could form the basis of eradication strategies. 
10.4 Eradication therapies 
Several different strategies have been evaluated, such as per oral antibiotic 
treatments and faecal transplantation. There is, however, currently no therapy or 
method recommended for decolonization of EPE (225). Can the intestinal 
colonization with EPE be eradicated with a drug or therapy? Could future vaccines 
target EPE or selected clones of EPE causing severe infections? 
Such eradication therapies are neither possible nor desirable for all patients, as 
instant recolonization is likely in high endemic countries, and based on the 
discussion in the section on prolonged colonization, it is still a matter of debate if  
complete eradication is at all possible. 
Targeting and eliminating virulent EPE strains causing repeated or invasive 
infections, however, is highly desirable particularly in specific populations, e.g. 
immunocompromised hosts. Since colonization in itself  is not harmful, such 
eradication therapy must have a clinically relevant number needed to treat (NNT), 
with few or no adverse effects. 
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10.5 Host immune response to EPE 
colonisation/infection. 
Numerous clinical studies and new laboratory techniques such as whole genome 
sequencing have provided valuable insights of virulence and resistance genes of 
EPE during the past decades.  
But little is known about the host immune response to EPE colonization and 
infection. Is there a humoral response to the CTX-M-type beta-lactamase? 
Recurrent infections with E. coli in general and ESBL-producing E coli in particular, 
most notably urinary tract infections, are not uncommon. Such infections have been 
demonstrated to occur with bacteria carrying identical beta-lactamases suggesting 
that infections with E. coli do not induce protective immunity (226). But it is not 
known whether specific antibodies directed against the specific beta-lactamases are 
generated, neither IgA nor IgG, in what circumstances they may be and what 
functional role such antibodies may have. If  antibodies are produced, could they be 
used as diagnostic tools or even for adjunctive therapy for EPE infections or 
colonization? 
Why are some individuals only colonized with EPE and others develop infections? 
Is this due to bacterial characteristics or underlying conditions of the host? Is it a 
combination of the two? Is the host immune response to EPE colonisation/infection 
involved? If so, in what way? 
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11 Overall aim of the thesis 
The overall aim of the thesis was to study different aspects of EPE acquisition, 
colonization, loss of colonization and infection. The included studies specifically 
examine spread to or from companion animals, risk factors for carriage persistence, 
an updated assessment of acquisition from international travel, an eradication trial 
and humoral response following infection. 
11.1 Specific aims  
• To study potential and frequency of spread of EPE between humans and 
dogs of the same household (Paper I). 
• To identify risk factors associated with prolonged intestinal carriage of EPE 
(Paper II). 
• To identify to what extent patients with EPE infection/colonization is 
adequately informed about EPE (Paper II). 
• To evaluate if a probiotic mixture could eradicate intestinal carriage of EPE 
(Paper III).  
• To investigate if specific IgG antibodies directed against the ESBL enzymes 
CTX-M-15 and CTX-M-27 can be detected in patients having undergone 
EPE bacteremia (Paper IV). 
• To re-assess the rate of EPE carriage in patients with travellers’ diarrhoea 
ten years after an initial study in the same region was performed (Paper V). 
• To identify if patients with travellers’ diarrhoeal carry carbapenem-resistant 
Enterobacterales (Paper V). 
• To study phenotypic and genotypic traits of EPE identified, and likely 
acquired during travel, with special regard to antimicrobial resistance and 
virulence factors (Paper V). 
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12 Patients and methods  
Below is a summary of the ethics, patients, setting, laboratory methods and research 
methodology used in this thesis. For detailed description of the methodology used 
for all papers, please see the Materials and Methods sections of each paper.  
12.1 Ethics 
All included studies in this thesis were approved by a local ethics committee 
(Regional Ethical review Board Lund District Court; DNR2013/713, 
DNR2016/304, 2016/803, 2018/143 and 2016-740). 
12.2 Setting 
All five studies were conducted in the Skåne County, located in the south of Sweden 
with nearly 1.4 million inhabitants in 2019 (227). In Skåne, there is only one 
laboratory for clinical microbiology, serving the whole county, and no private 
alternatives exist.  In Paper I, additional individuals were recruited to the control 
group (dog owners with a faecal culture negative of EPE) in Uppsala, Sweden. The 
majority of the control group was, however, recruited in Skåne. 
12.3 Paper I 
 
Paper I was a cross sectional case control study. Patients were recruited from the 
Department of Clinical Microbiology, Skåne University hospital. In an 18-month 
period between 2014 and 2015, 498 patients were positive for EPE in at least one 
faecal culture. Case records were reviewed; new-borns receiving neonatal care and 
patients with therapeutic/prophylactic antibiotic treatment were excluded. 
Furthermore, a permanent address and a telephone number was needed in order to 
contact the patient and to be able to send material for EPE cultivation of the patient 
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and the household dog. Many of the 498 patients positive for EPE during this time 
were recently arrived refugees, unable to be included in the study. One cannot be 
certain but bringing or acquiring a companion animal were likely not a priority for 
these refugees.  
Patients were contacted by telephone and asked about dog ownership or if a dog 
was present in the household. The control group, individuals with a negative EPE 
faecal culture, was recruited from the vicinity of the research group. Unfortunately, 
we did not register the exact number of patients excluded after case records were 
reviewed, neither how many patients that were contacted by phone. This is regretful 
and should have been recorded and disclosed in the manuscript. However, not one 
dog owner declined participation. 
12.4 Paper II  
Paper II was a prospective cohort study. Inclusion of patients was conducted 
between 2016-2017, during which 2 148 adult patients with a verified culture of 
EPE in urine, blood, faeces or any other location were eligible for inclusion. Case 
records were reviewed, exclusion criteria were alcohol or substance abuse, severe 
psychiatric disorder, immunosuppressed patients (e.g., immunodeficiency, ongoing 
cancer treatment, neutropenia/leukopenia, treatment with TNF-α-inhibitors), 
inpatient care, patients with chronic venous catheters, dementia or inability to 
provide informed consent, and newly arrived refugees. In all, 820 adult patients with 
at least 1 documented positive ESBL-culture from blood, wound, cervix, urine or 
faeces were contacted by mail and asked to submit one faecal sample for 
microbiological analysis. We defined prolonged EPE colonization as the prevalence 
of EPE in the faecal culture obtained at least 3 months from the first positive EPE-
culture. Of the 820 adult patients invited to take part in the study, 677 declined to 
submit a faecal sample and 143 accepted.  
12.5 Paper III  
Paper III was a randomized, single blinded clinical trial of a probiotic mixture. The 
patients of paper III consisted of the 81 adult patients with no evidence of 
immunosuppression of paper II who were positive for EPE in the follow up faecal 
culture, with the exception of one patient who declined further participation after 
the (EPE positive) faecal culture had been obtained. Thus, eighty patients were in 
total randomized to placebo or probiotic treatment. 
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All patients were asked to submit faecal samples for selective ESBL-culturing 1, 3, 
6 and 12 months after initiation of probiotics or placebo. Hence, the first follow-up 
faecal culture was taken during the treatment and the second one 4 weeks after the 
intervention was completed. 
The primary endpoint was successful decolonization defined as three consecutive 
ESBL-negative faecal samples after completed intervention (at time-points 3, 6 and 
12 months).  
12.6 Paper IV  
Paper IV was a cross sectional observational study with a control group. Eligible 
patients for inclusion in the study were adult patients who had been diagnosed and 
survived an ESBL-producing E. coli or Klebsiella spp. bacteremia during the years 
2016 and 2017, n = 147. The exclusion criteria of this study were primary residency 
outside Skåne County, non-Swedish citizenship, cognitive impairment, and 
previous bacteremia with  EPE. The control group consisted of patients with 3GCSE 
bacteremia during the same period. After case records had been reviewed, 121 
patients were eligible in the EPE group and invited to participate, of which 62 
patients declined or did not reply. 
In the 3GCSE group, 135 patients were assessed for inclusion. At this point in time, 
this was the number of patients in the EPE group thought to be eligible for inclusion. 
Out of these, 93 patients declined or did not reply. Thus, 42 patients were included 
in the 3GCSE group. 
12.7 Paper V 
Paper V was a cross sectional cohort study. Clinical samples sent to the Department 
of Clinical Microbiology, Skåne University Hospital between February 2017 and 
January 2018 for culture of Campylobacter, Salmonella, Yersinia or Shigella, for 
which the referral stated foreign travel, were included in the study according to staff 
availability. In total, 314 cultures were included and selectively cultivated for EPE 
according to the hospital routines. Out of these 314 cultures, the referral stated 
‘asymptomatic’ for 11 patients (restaurant students/employees) and where thus 
excluded from the study. WGS was performed on all available EPE strains. 
Countries were categorized according to the United Nations Statistics Divisions 
(228). 
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Figure 15. Schematic view over study design for each study. 
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13 Laboratory methods for detecting 
EPE 
When screening for ESBL-producing bacteria, commonly referred to as 
selective cultures, chromogenic culture media are used. The medium 
contains a chromogenic substrate which yields a specific colour to each 
species of microorganisms. Ceftazidime and meropenem are used as markers 
for ESBL and carbapenem resistance, respectively. After 16-18 hours of 
incubation, the plates are inspected. Colonies of E. coli are pink/burgundy 
whereas  Klebsiella/Enterobacter/Serratia/Citrobacter are green/blue to 
brown/green and Proteus/Providencea/Morganella are dark to light brown. 
Classification according to species is done with MALDI-TOF. Putative 
ESBL strains are then further analysed using the MAST test. Selective 
culture for EPE with susceptibility testing according to the EUCAST disk 
diffusion test methodology was performed in paper I, II, III and V. 
13.1 The MAST-test 
The MAST-test (Mast group Ltd, Liverpool, England) is an easy to use, phenotypic 
test for detecting EPE. As previously stated, classic plasmid mediated ESBL, in 
Sweden referred to as ESBLA, is inhibited by clavulanic acid. AmpC, in Sweden 
referred to as ESBLM, is inhibited by cloxacillin. This is used in the MAST-test at 
the clinical microbiology unit to differentia between ESBL and AmpC. If 
AmpC/ESBL is suspected, the isolate is incubated (35-37°C ) overnight. The third-
generation cephalosporin cefpodoxime is used as base on the plate. 
76 
Figure 16. Schematic presentation of the premise of the MAST test. 
Figure 17. Interpretation of MAST-test 
When zones are measured, sizes ≥ 5 mm are used to determine inhibition. 
Consequently, in zone sizes between 0 - 4 mm, no inhibition has been seen. If the 
result is negative, or when the result is not assessable, further analysis using 
polymerase chain reaction (PCR) is performed on the strain. 
Multiple beta-lactamases within one organism (e.g. combined ESBL and AmpC) 
can make phenotypic tests difficult to interpret. Furthermore, phenotypic tests like 
the MAST-test are not able to differentiate between chromosomal or plasmid-
mediated AmpC (pAmpC). For Klebsiella, this does not constitute a problem, as 
Klebsiella bacteria do not possess chromosomal AmpC. The detection of pAmpC in 
klebsiella is therefore straightforward. For E. coli, however, the situation is a bit 
more complicated, as it has both chromosomal and plasmid mediated AmpC. 
Genotypic verification is needed to conclude that the strain is in fact a pAmpC. 
MAST-tests cannot differentiate between the different types of pAmpC. For this, 
PCR is needed. The NordicAST flowchart to detect ESBLA and ESBLM in 
Enterobacterales is displayed in Figure 18 and 19, respectively. 
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13.2 PCR  
PCR is a widely used technique within diagnostics of infectious disease for detecting 
the DNA of pathogens. In medical microbiology, PCR followed by DNA 
sequencing is used to identify and characterize genes and genetic sequences that 
may be related to phenotypical traits, such as resistance and virulence. 
It involves the exponential amplification of small fragments of DNA through 
multiple cycles of denaturation, primer annealing and amplification. 
The result is millions of copies of DNA which enables detailed studies on molecular 
level. The PCR technique was developed during 1980s by Karey Mullis, who later 
was awarded the Nobel prize in chemistry for this achievement. It has become 
invaluable for determining and analysing the worldwide spread of ESBL. In 
particular, PCR based methods for determining beta-lactamase according to CTX-
M or pAmpC-type are standard use today (90, 229). PCR was used in paper I, IV 
and V. 
 
Figure 18. The NordicAST flowchart to detect ESBLA in Enterobacterales. 
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Figure 19. The NordicAST flowchart to detect ESBLM in Enterobacterales. 
13.3 Multiple locus VNTR analysis (MLVA) 
MLVA a method for epidemiologic typing and can be used in prokaryotes as well 
as eukaryotes. In bacteriology, it is a useful tool to determine phylogenetic 
relationships of different isolates, which can be used for research purposes but also 
for uncovering outbreaks of, for instance, drug resistant bacteria in health care. In 
the genes of different bacterial isolates, specific sequences of nucleic acids are often 
identical. However, these sequences are repeated throughout the genes, and the 
number of repetitions is unique for each organism. The repeats are known as 
variable number of tandem repeats, VNTR. For E. coli, primers targeting ten 
different pairs of loci of the genome were selected for paper I in this thesis 
(CVN001, CVN002, CVN003, CVN004, CVN007, CVN0014, CVN0015, 
CCR001CVN0016 and CVN0017, respectively) (230).  By using PCR the number 
of repeats were analysed. The number of repeats is found by assessing the weight 
of the entire block of VNTR divided by the weight of the sequence. In identical 
isolates, the number of repeats is identical whereas in different isolates the number 
of repeats differs. MLVA was used in paper I. 
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13.4 MLST  
Using PCR and DNA sequencing, a set of housekeeping genes (typically seven 
different loci) are analysed for nucleotide differences. MLST can be used to 
differentiate between strains of bacteria of the same species, e.g. in situations of 
outbreaks and for phylogenetic analysis if the sequences are concatenated. Even 
though WGS is becoming more available and in many instances replacing MLST, 
the latter has been used for a long time and classification of E. coli strains according 
to sequence type is still highly relevant. Although MLST was not used specifically 
for any of the papers in this thesis, sequence types were determined in Paper IV, 
using data from WGS. 
13.5 ELISA  
Simplified, ELISA is used to detect the presence of a ligand, commonly a protein in 
a liquid. In this thesis, the proteins used are antibodies: anti-CTX-M-15 and anti-
CTX-M-27. They bind to the walls/bottom of the microplate. The optical density, 
i.e. the measure of absorbance, of the liquid is compared to standard curve and a 
cut-off is applied. ELISA was used in paper IV. 
13.6 WGS  
Due to its small genome size, Haemophilus influenzae was the first organism to have 
its entire genome sequenced in 1995 (231). Today a whole genome shotgun method 
is used, where many overlapping DNA fragments are sequenced in parallel. A 
computer software assembles these fragments into larger contigs and (sometimes) 
eventually chromosomes. Before WGS, subtyping of E. coli was done by measuring 
antibody levels against O- and H-antigens, and MLST. WGS can more accurately 
subtype different strains of E. coli, as well as provide useful information of 
resistance and virulence genes (232). 
13.7 Statistics 
Numerical data was summarized as median and categorical data as proportions (%). 
For comparison between groups different tests were used for 
parametric/nonparametric, continuous or categorical data. A two-sided exact 
significance of ≤0.05 was considered statistically significant. In Paper II and IV, 
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univariate logistic regressions were performed. Odds ratios (OR) with 95% 
confidence interval (CI) were reported. In Paper II, a stepwise forward multivariate 
logistic regression model was used. Additionally, the statistical method of weighting 
was used to account for  unequal response rates. For paper III, imputation and a 
sensitivity analysis was performed. The statistical analyses were performed using 
IBM SPSS Statistics for Macintosh, Version 25.0. Armonk, NY: IBM Corp. 
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14 Results  
14.1.1.1 Paper I 
In the EPE group, twenty-two individuals from twenty-two different households 
were confirmed EPE carriers as determined by faecal cultures. The age of these 
individuals ranged from 1 to 82 years. Of these, twenty carried ESBL-producing E. 
coli, one individual also carried an ESBL-producing K. pneumoniae. One person 
carried a pAmpC-producing E. coli and another an ESBL-producing K. pneumonia. 
Of the twenty-two households with individuals carrying EPE, dogs of 2 households 
(9%) were EPE positive. In each of these households, two additional persons were 
screened for EPE, but all four were negative. In the control group, none of the 29 
humans nor dogs were EPE positive. 
In household one, the strains of E. coli found in the human and one of the dogs were 
determined to be identical using MLVA. The other family members, both adults, 
and the second dog had negative cultures.  
In household two, one human and two dogs were determined to carry pAmpC-
producing E. coli. The pAmpC-producing E. coli isolated from the child and from 
one of the dogs was determined to be identical by MLVA. The other dog had a 
similar but not identical pAmpC-producing E. coli as determined by MLVA. The 
other family members cultured for EPE were negative. 
14.1.1.2 Paper II 
In paper two, we included a total number of 143 patients in the study. They carried 
a total of 147 EPE-strains, of which 134 (91%) were E. coli, 12 (8%) were K. 
pneumoniae and 1(1%) was Proteus spp. Out of the 147 strains of EPE, 134 (91%) 
were inhibited by clavulanic acid (ESBLA) 10 (7%) were inhibited by cloxacillin 
(AmpC or ESBLM) and 3 (2%) were inhibited by both. In the follow up faecal 
culture after a minimum of three months, 81 patients (57%)  remained positive for 
EPE out of the initial 143 patients. Thus, 62 patients were negative in the follow up 
faecal culture. 
 
Data was obtained from medical charts and questionnaire and analysed for risk 
factors of prolonged EPE colonization. In the univariate model, urological 
intervention within 6 months (p=0.000), an original EPE-positive culture in urine 
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(p=0.009), a history of EPE infection (p=0.007) and travel to Asia and/or Africa 
within two years (p=0.020) were associated with a follow-up faecal sample positive 
for EPE.  
In the stepwise forward multiple regression model, urological intervention within 6 
months (p=0.007, odds ratio (OR) 4.32, 95% confidence interval (CI): 1.50–12.42) 
and history of EPE infection (p=0.028, OR 2.82, 95% CI: 1.12–7.10) remained 
significant risk factors for prolonged EPE carriage. Travel to Africa and/or Asia 
within the last 2 years (p=0.04, OR 0.42, 95% CI: 0.18–0.96) was associated with a 
reduced risk of prolonged EPE carriage. 
Table 8. Outcome of the stepwise forward multiple regression model. 
Step Variable OR CI 95%  p-value 
   Lower Upper  
Step 1 Urological intervention within 6 months 5.72 2.05 15.92 0.001 
Step 2 Urological intervention within 6 months 4.69 1.65 13.33 0.004 
 History of EPE infection 2.77 1.13 6.83 0.027 
Step 3 Urological intervention within 6 months 4.32 1.50 12.42 0.007 
  History of EPE infection 2.82 1.12 7.1 0.028 
  Travel to Africa and/or Asia within 2 years 0.42 0.18 0.96 0.040 
 
Out of 820 patients approached in this study, only 143 (17%) were willing to submit 
a faecal sample. Thus, 677 (83%) individuals were unwilling to participate. An 83% 
loss could risk the external validity of our results. Therefore, statistical weighting 
was performed on the variables that were associated with prolonged carriage of EPE 
(before weighting), as well as age, sex and Charlson comorbidity score. 
Table 9. Comparison of baseline characteristics between the patients included in the study and patients that did not 
provide a follow-up sample. 
Baseline characteristics 
Patients included 
(n=143) 
Patients not included 
(n=677) 
P-
value 
 
Age, median (range) 67 (19-87) 60  
Female sex (%) 92 (64) 456 (67) 
0.485
8 
Charlson comorbidity score, median (range) 0 (0-7) 0 (0-8)  
History of EPE infection (%) 116 (81) 458 (68) 0.001 
Urological intervention within 6 months (%) 36 (25) 129 (19) 0.097 
Resistance to ciprofloxacin + 
trimethoprim/sulfamethoxazole (%) 71 (50) 250 (37) 0.01 
 
Most of the variables compared did not differ significantly between the patients 
included and not included. 
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There was, however, a difference in the percentage of patients with resistance 
against both ciprofloxacin and trimethoprim/sulfamethoxazole (p=0.01) and 
infected compared to colonized (p=0.001) in the two groups. In order to adjust for 
this, statistical weights were computed with regard to resistance and history of EPE 
infection.  
14.1.1.3 The process of weighting 
When using weighting based on two different variables, two different 2x2 
contingency table are used. One cross tables that shows how the variables are 
distributed within the patients included in the study, and one cross table for all 
patients. 
Table 10. Cross table for all patients 
 
Table 11. Cross table for included patients 
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As seen from table 10 and 11, there was a discrepancy in the proportion of patients 
with no history of EPE infection and at the same time no resistance against 
ciprofloxacin + trimethoprim/sulfamethoxazole between all patients (17.2%, 
underlined) and included patients (7.0%, underlined). 
The aim of weighing is to level out this difference. The weights are displayed in 
Table 12. 
Table 12. Computed statistical weights. 
Variable Weight 
History of EPE-infection and Bacteria resistant to both ciprofloxacin and Trimethoprim/Sulfamethoxazole 0.6976 
History of EPE-infection and Bacteria not resistant to both ciprofloxacin and Trimethoprim/Sulfamethoxazole 1.0070 
No history of EPE-infection and Bacteria resistant to both ciprofloxacin and Trimethoprim/Sulfamethoxazole 1.0771 
No history of EPE-infection and Bacteria not resistant to both ciprofloxacin and Trimethoprim/Sulfamethoxazole 2.4589 
In brief, the weight is equal to what the number highlighted in red in table 10 (7.0) 
has to be multiplied with to equal the number highlighted in green in table 10 (17.2). 
In this case ≈ 2.46. Corresponding calculations are then done for results of the other 
variables, as seen in Table 12. Using these weights, a new cross table is constructed 
for the patients included in the study.  
Table 13. New cross table for included patients using weights. 
As seen in Table 13, the new, weighted results for the included patients are similar 
to the results of all included patients, compared to table 10. Thus, the new, computed 
results better represent the results of all patients eligible for the study. 
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When the values are used in the multiple regression model, they either have a 
“boosting” or “reducing” effect. The answers from the underrepresented group (no 
history of infection, bacteria not resistant to ciprofloxacin + 
trimethoprim/sulfamethoxazole) will have greater impact, and the overrepresented 
(history of infection, bacteria resistant to ciprofloxacin + 
trimethoprim/sulfamethoxazole) less impact. 
When patients were asked if they were aware of their EPE infection/colonization 
before being contacted by the study group, sixty-one patients (50%) stated that they 
were unaware of this.  
14.1.1.4 Paper III  
A total of 80 patients were included in this placebo-controlled, single blinded, 
randomized controlled trial. It was designed as a superiority trial, investigating the 
effectiveness of a probiotic mixture compared to placebo in eradicating chronic 
(defined as at least three months) intestinal EPE-carriage. Patients were randomized 
to placebo (n = 40) or probiotics (n = 40). The median age was 68 years in both 
groups. The number of females in the probiotics group was 23 (58%) and in the 
placebo group 28 (70%).  
At the end of the trial, 12.5% (5 out of 40) of the patients in the probiotic group had 
achieved successful eradication of EPE, as defined by the primary outcome, in the 
intention to treat analysis. In the placebo group, 5% (2 out of 40) of the patients had 
achieved successful eradication of EPE (odds ratio 2.71; 95% CI 0.49–14.9; p = 
0.24). 
When individuals with fully evaluable outcomes where included only, successful 
intestinal decolonization was achieved in five out of 33 study persons (15%), 
compared with two out of 33 (6%) in the control group (p = 0.23). 
Of great importance, though, is the fact that two patients in the probiotic group (of 
the 5 patients with successful EPE eradication) that did meet study criteria of 
eradication, had clinical cultures positive for EPE during the follow up time. One 
had multiple urinary cultures and the other one had a faecal culture, positive for 
EPE. These cultures were all taken in a clinical setting, beyond the study protocol, 
with identical antibiograms compared to the cultures of the study protocol. The two 
patients both achieved successful eradication of EPE as defined by the primary 
outcome but were clearly not EPE negative. This reflects the limited sensitivity of 
selective faecal cultures even when several samples are obtained as in this study. 
 
Thus, of the 5 patients with successful eradication of EPE, as defined by the primary 
outcome used in our study, 2 patients evidently did not have successful eradication. 
Using this information, 7.5% (3 out of 40) of the patients in the probiotic group had 
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achieved successful eradication of EPE, compared to 5% (2 out of 40) in the placebo 
group (OR 1.54, 95% CI 0.24-9.75; p 0.64).  
 
a) 
 
 
b) 
 
Figure 20. Results of the intervention, a) intention to treat analysis, b) per protocol analysis. 
14.1.1.5 Paper IV 
A total of 59 patients were included in the EPE-group, and out of these 47 patients 
had blood isolates carrying either blaCTX-M-15 or blaCTX-M-27. Of these 47 patients, 13 
patients (28%) carried IgG antibodies to the corresponding CTX-M-type. In 
contrast, the control group consisted of 42 patients with 3GCSE bacteremia of which 
only 9.5% of patients (4 out of 42) were positive for anti-CTX IgGs (p=0.03). 
 
IgG directed against CTX-M-27 were found in 5 patients with EPE bacteremia, but 
antibody specificity did not correspond to the genotype of bacteria isolated from 
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blood; 4 patients were infected by E. coli expressing the blaCTX-M-15 gene and 1 
patient had an EPE blood isolate carrying blaCTX-M-14. 
Table 14. Genetic profile of EPE blood isolates and prevalence of antibodies in the EPE and 3GCSE group. 
CTX-M beta-lactamasea Only anti-CTX-M-
15 IgG (n) 
Only anti-CTX-M-27 
IgG (n) 
Both anti-CTX-M-15 and  
anti-CTX-M-27 IgG (n) 
EPE group (n=53) 2  7 9  
     blaCTX-M-15 (n=41) 2 4b 8 
     blaCTX-M-27 (n=6) 0 2 1 
     blaCTX-M-14 (n=6) 0  1b 0 
3GCSE group (n=42) 2 2 0 
 
a The following blaCTX-M genes were also identified in 5 clinical isolates, but patients 
did not develop cross-reacting anti-CTX-M15 or anti-CTX-M-27 IgGs; blaCTX-M-138 
(n=2), blaCTX-M-174 (n=2), and blaCTX-M-79 (n=1). The blaCTX-M gene of one blood 
isolate could not be determined. 
b False positive, i.e., antibody prevalence but not to the corresponding genotype. 
(a) EPE group 
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(b) 3GCSE group 
Figure 20. Distribution of antibody levels of anti-CTX-M-15 and anti-CTX-M-27 IgG for the EPE (a) and the 3GCSE 
group (b).  
ELISAs were performed to determine the presence of anti-CTX-M-15/CTX-M-27 
IgG antibodies. Sera were analysed in duplicates and mean values of two 
measurements for each patient were used in the final data analysis. OD = optical 
density. 
14.1.1.6 Paper V 
Out of 303 patients with travellers’ diarrhoea, eighty-four patients (28%) carried a 
total of 92 strains of EPE. The majority (92%) were E. coli and the remaining 8% 
were K. pneumoniae. In total, 85 strains were inhibited solely by clavulanic acid 
(ESBL), 9 strains were AmpC-producing, of which 4 strains expressed phenotypical 
inhibition both for cloxacillin and clavulanic acid 
The EPE prevalence of 28% is slightly higher than in an investigation in the same 
population one decade earlier (24%), but the difference was not statistically 
significant(21). 
When comparing EPE colonization between different continents, highest rates were 
seen from Africa (54%), Asia (45%) and North America and the Caribbean (22%).  
For specific countries, highest EPE colonization rates were seen for India (100%), 
Egypt (71%), Tanzania/Zanzibar/Kenya (80%), Cuba (57%) and South Africa 
(50%).  
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No strains resistant to imipenem, meropenem, ceftazidime-avibactam or amikacin 
were found in the study.  
All 92 EPE strains in the study were susceptible to meropenem, imipenem and 
ceftazidime-avibactam. Susceptible increased exposure was found for piperacillin-
tazobactam (12%), ceftazidime (17%), tobramycin(%), amikacin (2%), 
trimethoprim-sulfamethoxazole (1%), ciprofloxacin (7%) and temocillin (92%). 
Resistance was found for piperacillin-tazobactam (9%), ceftazidime (78%), 
ceftolozane-tazobactam (17%), gentamicin (24%), tobramycin (23%), 
trimethoprim-sulfamethoxazole (67%), ciprofloxacin (47%) and temocillin (8%). 
There was no difference in proportions of patients positive for Campylobacter, 
Salmonella, Yersinia or Shigella in the EPE colonized (6.0%) compared to the EPE 
negative group (5.9%) (p=1).  
Out of 86 strains available for WGS, 47 different sequence types were identified, of 
which 3 where novel. The most common were ST38 (n=9, 11%) and ST10 (n=7, 
9%). Only 5 strains belonged to the widely distributed clone ST131.  
Most E. coli isolates belonged to phylogroup A (n=32, 41%) or D (n=25, 32%). Less 
prevalent were B2 (n=8, 10%), B1 (n=4, 5%) and F (n=2, 3%). 
For more than half of the E. coli strains (57%), an intestinal pathogenic pathotype 
was found, with EAEC (33%), and EIEC (22%) most commonly prevalent. One 
ETEC, one EPEC and no EHEC strains were found. For 27 isolates, no enteric 
pathotype could be determined.  
Furthermore, 43% were either ExPEC or UPEC, and 30% carried genes shared by 
ExPEC/UPEC and EAEC or EIEC. There was no statistical difference in the risk of 
carrying an ExPEC/UPEC strain and travel destination (region).  
Out of the 79 E. coli isolates, 76% of the strains carried at least one type 1-fimbriae 
gene and 75% carried at least two. Furthermore, 30% of the strains carried at least 
one pap (p-fimbriae) gene and 27% carried at least two. 
Out of 86 strains available for WGS, 138 different beta-lactam resistance genes were 
identified in total. ESBL beta-lactamases found were blaCTX-M-15 (n=62), blaCTX-M-27 
(n=9), blaCTX-M-14 (n=7) and blaCTX-M-55 (n=3). pAmpC genes found were blaDHA-1 
(n=4), blaCMY-2 (n=3), blaCMY-42 (n=2). Other beta-lactamases found were blaTEM-1B 
(n=29), blaOXA-1 (n=11), blaTEM-35 (n=4), blaSHV-199 (n=2), blaSHV-27 (n=2), blaSHV-106 
(n=1), blaSHV-60 (n=1), blaTEM-1C (n=1), blaSHV-159 (n=1), blaOKP-B-12 (n=1), blaOKP-B-14 
(n=1), blaOKP-B-3 (n=1).  
Regarding non-beta-lactam antibiotics, carriage of antimicrobial resistance genes 
were common for these strains, but corresponding phenotypical resistance was rare. 
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Of the 86 genotyped EPE strains, 79% carried resistance genes for resistance against 
aminoglycosides, 51% to fluoroquinolones, 77% to sulphonamides, 78% to 
trimethoprim, 7%  to fosfomycin, 24% to chloramphenicol, 12% to aminoglycosides 
and fluoroquinolones (combined), respectively. Genotypic and phenotypic 
expression of AmpC correlated well (n=9). 
Figure 20. Prevalence of EPE with respect to regions. 
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15 Discussion 
What information does my thesis add to this field of research? How do the findings 
relate to other studies in the field? What are, if any, the clinical implications? 
This thesis sheds some new light on the research area of ESBL-producing bacteria. 
The strengths lie in its diversity. It includes five studies that are either prospective 
or cross sectional. On the one hand, it includes studies where the main share of work 
was done in the laboratory and on the other hand a randomized clinical trial on 
patients. Since I am principally a medical doctor working in a hospital, I have 
approached the theme of EPE with a clinician’s eyes.  
15.1.1.1 Paper I 
Paper I gives novel insight into the spread of EPE, as it was the first study to report 
the sharing of identical EPE strains between humans and dogs of the same 
household. This indicates that within a household transmission of EPE between 
humans and dogs can take place. The study demonstrates proof of principle, but a 
statistically significant difference compared to the control group could not be 
shown, most likely due to the small sample size. The directionality of transfer was 
unknown. 
The possibility of an outside source of these EPE-strains, such as water, foodstuff 
or an environmental source, spreading to humans and dogs of household 1 and 2, 
was not, however, evaluated. This seemed less likely, taken into consideration that 
no other humans were positive for EPE in household 1 and 2. Still, looking back, 
perhaps the word “evidence” used in the title should have been replaced with 
“suggestion”. 
Yet, since our study was published in 2016, additional studies have confirmed our 
results of co-carriage of identical EPE in humans and dogs of the same household. 
This has been interpreted by the authors as household transfer.  
One case report from Finland in 2018 reported the co-carriage of an identical E. coli 
strain carrying carbapenemase NDM-5 and CTX-M-9 between humans and dogs 
(233). Although the transfer route was not investigated, they presumed the humans 
transmitted the strains to the dogs of the household. 
A Dutch cross-sectional study investigated the prevalence of EPE in humans, dogs 
or cats of the same household (234). EPE was detected in 10.6% of the dogs 
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(59/555), 1.4% of the cats (4/285) and 3.8% of human participants. No co-carriage 
was seen for humans and cats, but in seven households both humans and dogs 
carried EPE. Out of these, five carried the same ESBL gene, as determined by WGS; 
three of these were regarded identical based on analysis of core-genome and plasmid 
content. The authors concluded a 5% risk of co-carriage between humans and dogs 
in household where at least one dog is EPE positive. 
Thus, the sharing of identical EPE strains between humans and dogs of the same 
household does occur. The route is unknown.  
15.1.1.2 Paper II 
As a clinician, it can be frustrating to decide which empirical treatment is suitable 
for the patient in the emergency room with any previous EPE positive culture. 
Today, if a patient has had such a positive EPE culture, even if this was many years 
ago, that patient is considered to be a lifelong carrier of EPE and at risk of such 
infections. Even though the work of Paper II has not studied prolonged carriage of 
EPE in relation to a risk of infection, continued EPE colonization could be 
associated to an increased risk of developing EPE infections. 
In these cases, giving empirical antibiotic treatment not covering for the EPE, may 
risk the health, and in worst case, the life of the patient. On the other hand, a broader 
antimicrobial treatment increases the risk of developing resistant bacteria. 
Furthermore, it is an inferior option considering the global ecological situation of 
antibiotic resistance. At present, it is not known for how long a positive EPE culture 
is relevant and clinically important (if such a general question has a clear answer at 
all). A recent study proposed a carbapenem-sparing regime as empirical treatment 
in non-critically ill patients colonized with EPE, unless a urinary tract infection is 
suspected (235). 
Paper II gives some new information on this matter. It examines risk factors for 
persistent EPE positivity if the culture is repeated at least three months after an EPE 
infection/colonization. It identifies urological intervention and a history of EPE 
infection as variables independently associated with prolonged intestinal 
colonization with EPE. 
Travelling to Africa and/or Asia within 2 years was associated with a decreased risk 
of prolonged intestinal colonization with EPE. This could reflect transient changes 
in the microbiota related to travel exposure, and possibly relate to the resilience 
phenomenon as discussed in the section of microbiota. That is, the ability of the gut 
flora to return to an equilibrium state following a disturbance. With high level of 
resilience comes faster restoration to equilibrium, which could theoretically be 
associated with clearance of acquired strains of EPE. Thus, if the EPE strains are 
acquired during travel to Africa and/or Asia restoration to equilibrium could mean 
the clearance of EPE. However, more research is needed as these are mere theories. 
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Studies of risk factors concerning prolonged intestinal carriage of EPE are few, and 
epidemiological studies investigating this are urgently needed. Since our study was 
published, a recent study found prolonged EPE carriage in 59.4% (one month) and 
36.5% (six months) (236) Interestingly enough, in prolonged EPE colonization, 
82% of strains were identical. The remaining were considered plasmid transferred 
to other bacteria. Contrary to our study, this study identified travel to Asia as a risk 
factor for prolonged (six months) EPE carriage. Furthermore, additional risk factors 
were related to hygiene (not changing the kitchen towel daily) and to swimming in 
the sea. 
The results of regression models are dependent on what variables you choose. In 
total, eight variables were included in the multivariate regression model in our study. 
Statistical methods other than weighting could have been used, such as matching or 
imputation. However, these methods are in this case inferior to weighting.   
15.1.1.3 Paper III 
Can  EPE be selectively cleared from the intestines with some type of therapy? Paper 
III explores this in a clinical trial on patients using probiotics, which has been 
proposed as a method of EPE eradication (237). We performed a superiority study 
comparing probiotics to placebo. The study did not show a statistically significant 
difference between probiotics and placebo in eradicating EPE in chronic intestinal 
carriers. This is, nevertheless, an important result as other alternatives should be 
pursued. Each individual has its own unique microbiota, and perhaps there is not a 
single probiotic mixture that works for everyone.  
The study has a number of limitations that should be noted. The design did not allow 
full control of adherence to the treatment protocol, and compliance with the culture 
protocol was used as a proxy for treatment adherence. The editor and reviewers of 
this paper wanted to highlight the risk of a type II-error in the conclusion. Looking 
back, we fully agree that the study is underpowered and carries a risk of a type-II 
error. The power calculation on which the study was based was very optimistic, and 
a small or moderate, but clinically meaningful, treatment effect cannot be ruled out; 
an absence of evidence of an effect does not equal evidence of an absence of effect.  
Another limitation of the manuscript was the risk of bias accompanying the 
proportionally large number of missing outcome data. In the result, individuals with 
missing outcomes were included in the ITT analysis based on a BOCF (baseline 
outcome carried forward) assumption/imputation. This is a point of controversy, and 
many authors are inclined only to include evaluable outcome data in the analysis. It 
can thus be argued that the analysis noted as per-protocol in our study may be 
viewed as an ITT analysis based on individuals with evaluable outcomes. Such an 
approach would not have changed the results of the study but would have increased 
the risk of a type II error even further. 
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There are numbers of alternative ways of performing imputation of missing 
outcomes in order to minimize bias, including best/worst case imputation, latest 
observation carried forward (LOCF) and various multiple imputation techniques. In 
the manuscript, only the first of these was included as a sensitivity analysis but 
implied rather extreme assumptions based on the observed data. 
In conclusion, the result of this study found no statistical difference between 
probiotics and placebo in this cohort. If this study were to be used as the basis for a 
new RCT including a larger material, the minimum number of subjects needed in 
order to have sufficient statistical power to detect the same dichotomous primary 
endpoint could be calculated. With an anticipated difference in incidence of 7.5 %, 
an alpha of 5%, and a power of 80%, a minimum of 444 patients would need to be 
included. This is without adjustment for any loss to follow up.  
Similar to MRSA, where successful eradication of carriage can be achieved, 
decolonization therapies for EPE are urgently needed, in particular in the virulent 
clones with high impact on mortality and morbidity. This has to take into account a 
clinical meaningful difference of the therapy and spontaneous loss of EPE. 
15.1.1.4 Paper IV 
Paper IV breaks new ground. It is believed that antibodies will develop following 
an invasive infection, to protect the host from additional infections of that specific 
serotype. To the best of our knowledge, it has never before been shown that 
antibodies targeting the CTX-M-type beta-lactamase itself are involved in the 
humoral host response to EPE blood stream infections. Sometimes studies that 
investigate a novel field, as in Paper IV, can provide answers as well as raise 
questions.  
Some answers are provided. It seems clear that individuals having experienced EPE 
bacteremia more often have detectable IgG antibodies directed against the 
respective beta-lactamase than individuals having recently experience bacteremia 
with susceptible E. coli. It is also evident that far from all individuals with 
experienced EPE bacteremia have detectable CTX-M antibodies.  
Beta-lactamases are produced in the cytosol and, after being transported across the 
cytoplasmatic membrane, are principally located in the periplasmatic space. For an 
immune reaction to occur with antibody production, beta-lactamases must exit 
bacteria. It is less likely that the reverse is possible, i.e. antibodies can access ESBL-
type beta-lactamases in the periplasmic space. This needs to be further investigated.  
In what situations are the ESBL presented as an antigen to the immune system? 
When presented, is the ESBL always considered foreign, leading to formation of 
antibodies? Are IgA antibodies against ESBLs present in the mucosa of some 
patients? Can antibodies, in its natural form, or more likely linked to some kind of 
chaperone molecule, enter the periplasm? Could the antibodies inactivate beta-
lactamases, rendering more effective treatment options? 
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A relatively high proportion of cross-reactivity was seen between the different 
antibodies anti-CTX-M-15 and anti-CTX-M-27. The different CTX-M types are 
structurally similar, sometimes only differing as to one or more amino acids. The 
five different clusters of CTX-M share >94% genetic identity(86). This could 
perhaps explain the cross reactivity but needs to be furthered examined.  
As a diagnostical tool, the implications of our findings are limited. We may not be 
able to differ between certain types of CTX-M beta-lactamases in patients with 
previous EPE bacteremia. This could, however, be an advantage if these antibodies 
could be used as a potential adjuvant therapy. Structural similarity could potentially 
mean that an infection with a certain CTX-M type of beta-lactamase and IgG 
therapy does not have to fully correspond, for the adjuvant treatment to be 
successful. 
15.1.1.5 Paper V 
Previous studies of returning travellers have e.g. given us insight that travellers’ 
diarrhoea (TD) is associated with EPE acquisition. However, repeated studies of 
international travellers are important, also serving as sentinel studies for tracking 
import of carbapenem resistant Enterobacterales.  
Furthermore, studies investigating the EPE prevalence exclusively in TD patients 
are rare, and a further strength is that our cohort of travellers is unselected. Similar 
studies include travellers seeking medical advice pre-travel, which may narrow the 
geographical distribution down to countries where travellers need malaria 
prophylaxis, vaccine against yellow fever etc (22, 23). Additionally, sequencing of 
the strains has given interesting information about their genotypical resistance and 
pathogenicity. 
It is precarious to study global trends in antimicrobial resistance given differences 
in study samples, methods, travel pattern etc. Owing to increasing international 
travel and a rising prevalence of EPE in clinical cultures, this study was planned as 
a follow-up study one decade after the original study in the same low endemic 
setting. A similar methodology was used, and this allowed us for instance to 
investigate and compare the EPE prevalence from different countries as well as the 
prevalence of CPE. It is reassuring that the EPE prevalence in TD patients has not 
increased during the last decade.  
An apparent limitation of our approach is the lack of pre-travel cultures, and thus a 
lack of proof that the identified isolate is actually acquired during travel. 
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16 Limitations  
All studies have strengths and weaknesses. Below, the main limitations of my five 
papers are discussed. 
16.1 Potential limitations of internal validity. 
Firstly, small sample sizes and non-randomization of cohorts risk selection bias. All 
studies could have benefitted from larger sample sizes. In Paper I the same 
methodology in the laboratory of diagnosing EPE should have been used for humans 
and dogs. A larger sample size should have been used, and cases and controls should 
have been recruited from the same geographical area. 
In Paper II and IV, important variables for investigating risk factors could have been 
overseen in the statistical analysis. Variables included in the regression analyses 
were putative risk factors, and other, unknown, important variables could have been 
excluded. While this is not a matter of internal validity, it is a risk of underfitting, 
Furthermore, there are methodological concerns. The dichotomization into EPE- or 
no EPE-colonization is determined by a single selective faecal culture. The 
sensitivity of the faecal culture in determining EPE is not 100%, which reduces the 
negative predictive value. This theoretically affects all studies but Paper IV, where 
no faecal cultures were used. Preferably, several cultures should have been obtained 
in Paper II over a greater period of time. A control group of non-EPE patients could 
have been included, to investigate the amount of new EPE carriers during the same 
period of time. 
In Paper III, whether patients received probiotics or placebo should have been 
blinded also to the primary investigator. In fact, the manufacturer in Italy prepared 
for a double blinded study. 
Also, the randomization with lots from a secured box in a 1:1 style was likely too 
simplistic. This should have been electronic, perhaps randomized in blocks of eight, 
for instance.  
However, the major limitation was the power calculation which was optimistic and 
thus the population studied should have been larger. This would have reduced the 
risk of a type II error.  
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In Paper IV, the control group was too small. If the same study was to be repeated, 
it should have been twice the size of the case group, to increase the statistical 
precision. All patients included in the study, cases and control patients, should have 
been selectively cultured for EPE in faeces to investigate carriage of EPE in the 
control group.  
In Paper V, not all clinical samples from TD patients sent to the Department of 
Clinical Microbiology for culture of Campylobacter, Salmonella, Yersinia or 
Shigella were included. They were included according to staff availability, and the 
amount of cultures missed because of this was not registered. However, we believe 
that the risk of a systematic bias because of this is negligible. Furthermore, we relied 
on the information on the referral to the Department of Clinical Microbiology, 
Skåne University Hospital. This data was in no way validated and did not contain 
information on patient characteristics nor specific travel details. 
16.2 External validity (or lack thereof) 
One should be cautious to generalize one’s results. Particularly for Paper II, the 
selection and methodology could risk the external validity of our results. For Paper 
III, the results found specifically to Vivomixx® should not be generalized for all 
probiotics. 
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17 Future research 
There is still a knowledge gap in the area of intestinal colonization of EPE. There 
are several major questions that remain to be answered. 
First, can the once EPE colonized intestines ever be selectively cleared of EPE? In 
which patients does EPE disappear from the intestines naturally, without 
intervention? Is this depending on bacterial or patient characteristics, or both? Could 
an intervention, a method or therapy be used to reach this goal in chronic carriers? 
Currently, based on lack of beneficial evidence, routine decolonization of EPE 
carriage is not recommended (225). Oral antibiotics have been tried with no long-
term effect on intestinal EPE carriage (238). The overwhelming risk of increased 
resistance with this method could be potentially harmful, aggravating the problem. 
Furthermore, antibiotics combined with faecal transplantation did not eradicate 
intestinal EPE colonization compared to a control group (239). 
In EPE endemic regions, intestinal decolonization strategies could be futile, as new 
EPE strains would likely be introduced after completed intervention. However, in 
low endemic areas eradication of EPE is desirable. Also, particularly in virulent 
strains or in patients with recurrent invasive EPE infections, decolonization 
strategies would be desirable. 
Secondly, more research is needed why some people carry EPE strains in the 
intestines, but others become ill from infections of the same strain. If this is a matter 
of virulence traits only, all patients colonized with certain strains would develop 
infection. This is not an enigma reserved for scientists preoccupied with EPE strains 
but has puzzled infectious disease-doctors for ages; why do some people only carry 
certain bacterial strains, without getting ill, while the same strain can be lethal to 
other patients in close contact? 
Prospective, longitudinal studies are needed to investigate the natural course of EPE 
colonization. To avoid unnecessary usage of carbapenems, a clinical algorithm with 
high discriminatory accuracy would be very useful to determine if or when a prior 
EPE culture (of any localization) should be covered in the empirical treatment of 
severe infections. After how long is an old faecal EPE culture irrelevant and can be 
discarded when starting empirical antibiotics?  
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18 Clinical implications. 
Why is this thesis interesting for an infectious diseases clinician? What are the 
clinical implications from the present thesis? 
From Paper I we have learnt that humans should be cautious in interacting with a 
known EPE carrier. EPE transmission between humans and dogs do occur. 
Paper II taught us that patients with EPE in clinical cultures are largely uninformed 
that they carry an EPE. We need to improve our information to patients regarding 
what EPE is, clinical implications, hygiene aspects etc. Patients should obtain both 
oral and written information. Secondly, Paper II provided information about factors 
that are associated with increased (and decreased) risk of prolonged EPE 
colonization in patients. Theoretically, this could be useful when choosing empirical 
antibiotics for a patient with prior EPE in a culture. If this patient has had a clinical 
infection with an EPE and/or a urological intervention within the last six months, he 
has more likely a faecal culture with EPE. Furthermore, this could be of help when 
considering infection prevention measures. 
Considering the risk of a type-II error, Paper III showed that use of the probiotic 
Vivomixx was not associated with improved chance of EPE eradication compared 
with placebo. Other eradication therapies must be explored. 
Paper IV has brought us new insights on the host response to invasive EPE 
infections. A proportion of patients having experienced EPE bacteremia produce 
specific IgG antibodies against corresponding beta-lactamases. The clinical 
implications of this are potentially promising but warrant further investigation. 
Paper V emphasises the risk for patients with TD of carrying EPE after international 
travel to endemic areas, most notably south and east Asia as well as Africa. Most of 
the E. coli strains were intestinal pathogenic E. coli and a comparatively high 
proportion of the strains were ExPEC/UPEC, many expressing virulence 
genes pap and/or fim. Clinicians should provide antibiotics with EPE coverage for 
patients with severe infections after international travel, especially if there is a 
history of TD. 
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19 Conclusions 
Identical EPE strains with respect to bacterial species, antibiogram, genotype, and 
MLVA can, to a limited extent, be found in humans and dogs of the same household. 
Risk factors independently associated with prolonged intestinal colonization with 
EPE (more than three months) were urological intervention within 6 months and a 
history of EPE infection.  
Travel to Africa and/or Asia within the last 2 years was significantly associated with 
a decreased risk of becoming a long-term EPE carrier.  
Half of the patients with infection/colonization of EPE in Skåne were not adequately 
informed regarding their EPE status.  
The probiotic mixture Vivomixx® was not superior to placebo for intestinal 
decolonization of adult patients with chronic colonization of EPE.  
There is evidence that EPE bacteremia can trigger a host response with the 
production of IgG antibodies targeting the common ESBL-type beta-lactamases 
CTX-M-15 and CTX-M-27. 
A relatively high proportion of patients with travellers’ diarrhoea carry EPE when 
they return to Sweden, (28%). Highest colonization rates were seen from Africa, 
Asia and North America and the Caribbean.  
Despite increased travel and increased prevalence of EPE in clinical cultures, the 
rate of EPE carriage in patients with travellers’ diarrhoea did not significantly 
increase compared to the previous study 10 years ago conducted in the same setting. 
No imipenem, meropenem, ceftazidime-avibactam or amikacin-resistant strains 
were found in the study.  
Many different sequence types were found, and surprisingly only 5 strains belonged 
to the widely distributed clone ST131. In our cohort, 3 patients carried strains with 
STs that had previously never been reported.   
Most E. coli strains were intestinal pathogenic E. coli. A comparatively high 
proportion of the strains were ExPEC/UPEC, many expressing virulence 
genes pap and/or fim.  
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20 Populärvetenskaplig 
sammanfattning 
Kunskapsläget om bärarskap av antibiotikaresistenta tarmbakterier av typen ESBL 
(extended-spectrum beta-lactamases) är idag bristfälligt. Det är oklart hur länge 
bärarskapet fortgår, om och när bärarskapet upphör, hos vilka detta sker och om det 
går att påverka bärarskapets längd med farmakologisk behandling eller någon slags 
terapi. Mer kunskap behövs kring riskfaktorer för, och implikationer av, bärarskap 
av ESBL-bildande tarmbakterier (EPE). 
Den här avhandlingen syftar till att öka denna kunskap på flera sätt. Den undersöker 
nya smittvägar för EPE och riskfaktorer för att bli långvarig bärare av dem. 
Avhandlingen utvärderar också om probiotika kan ha effekt på detta bärarskap. 
Vidare undersöks kroppens immunrespons mot infektion med EPE och slutligen 
efterforskas i hur hög grad man idag ser bärarskap av ESBL-bildande tarmbakterier 
hos skåningar som har diarré efter utlandsresa. 
20.1.1.1 Delarbete I 
Delarbete I var en studie som inkluderade 22 hundägare med konstaterat bärarskap 
av ESBL och en kontrollgrupp på 29 hundägare utan ESBL. I två av 22 hushåll var 
både hundägare och hund positiva med identisk ESBL-bildande stam. 
20.1.1.2 Delarbete II 
Delarbete II var en prospektiv kohortstudie som undersöker riskfaktorer för 
långvarigt bärarskap (mer än 3 månader) av ESBL-bildande bakterier. Urologisk 
intervention och genomgången infektion med ESBL-bildande bakterier var 
associerat med förlängt bärarskap, och resa till Afrika/Asien senaste 2 åren var 
kopplad till minskad risk för förlängt bärarskap. 
Dessutom var 50% av deltagarna i studien omedvetna om att de var koloniserade 
eller hade haft en infektion med ESBL-bildande bakterier. Behandlande läkare 
behöver bli bättre på att ge muntlig och skriftlig information till patienter som bär 
ESBL-bildande bakterier. 
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20.1.1.3 Delarbete III 
Delarbete III var en prospektiv, randomiserad, placebokontrollerad studie som 
undersökte om probiotikan Vivomixx® kunde eliminera bärarskap av ESBL-
bildande bakterier jämfört med en kontrollgrupp som fick placebo. Ingen statistisk 
signifikant skillnad i behandlingsutfall mellan grupperna kunde påvisas.  
20.1.1.4 Delarbete IV 
Delarbete IV var en studie som undersökte förekomst av antikroppar mot ESBL-
enzymet CTX-M-15 och CTX-M-27. Patienter med antibiotikaresistenta 
tarmbakterier i blodet jämfördes med en kontrollgrupp av patienter med E. coli-
bakterier i blodet utan sådan särskild antibiotikaresistens. Vi fann en statistisk 
signifikant skillnad som tyder på att antikroppar mot ESBL-enzymet har en roll i 
immunförsvarets reaktion mot blodinfektioner med ESBL-bildande bakterier. 
20.1.1.5 Delarbete V 
Delarbete V var en kohortstudie av tvärsnittskaraktär som undersökte i vilken 
utsträckning utlandsresenärer som kom hem med turistdiarré hade bärarskap av 
ESBL-bildande tarmbakterier. Med molekylära metoder undersöktes bakterierna på 
DNA-nivå för förekomst av resistens- och virulensgener. Av 303 utlandsresenärer 
hade 84 patienter påvisad ESBL i avföringsprov (28%) Jämfört med en studie som 
gjordes på liknande sätt för 10 år sedan så var det en liten men icke statistiskt 
signifikant ökning. Det är betryggande att trots ökad förekomst av ESBL-bildande 
tarmbakterier i kliniska prover, samt ökat globalt resande, så ökade inte förekomsten 
av ESBL i avföringsprov hos resenärer med turistdiarré. 
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